Fatty hepatosis code for ICD. Alcoholic fatty liver

Hundreds of suppliers bring hepatitis C medicines from India to Russia, but only M-PHARMA will help you buy sofosbuvir and daclatasvir, while professional consultants will answer any of your questions throughout the therapy.

What is fatty liver: ICD code 10

The development of fatty hepatosis is based on the violation of metabolic processes in the human body. As a result of this liver disease, healthy tissue of the organ is replaced by fatty tissue.

At the initial stage of development, fat accumulates in hepatocytes, which over time simply leads to dystrophy of the liver cells.

If the disease is not diagnosed at an early stage and appropriate therapy is not carried out, then irreversible inflammatory changes occur in the parenchyma, which lead to the development of tissue necrosis. If fatty liver is not treated, it can develop into cirrhosis, which is no longer treatable. In the article, we will consider the reason for the development of the disease, methods of its treatment and classification according to ICD-10.

Causes of fatty liver and its prevalence

The causes of the development of the disease have not yet been exactly proven, but factors are known that can surely provoke the onset of this disease. These include:

  • completeness;
  • diabetes;
  • violation of metabolic processes (lipid);
  • minimal exercise stress with a nutritious daily diet high in fat.

Most cases of development of fatty hepatosis are recorded by physicians in developed countries with above-average living standards.

There are a number of other factors associated with hormonal disruptions, such as insulin resistance and the presence of sugar in the blood. You can not omit the hereditary factor, it also plays a big role. But still, the main reason is malnutrition, a sedentary lifestyle and excess weight. All causes are in no way related to the intake of alcoholic beverages, so fatty hepatosis is often called non-alcoholic. But if alcohol addiction is added to the above reasons, then fatty hepatosis will develop many times faster.

In medicine, it is very convenient to use the coding of diseases to systematize them. It is even easier to indicate a diagnosis on a sick leave using a code. Codes for all diseases are presented in International classification diseases, injuries and various health problems. The tenth revision is currently in effect.

All liver diseases according to the International Classification of the Tenth Revision are encrypted under the codes K70-K77. And if we talk about fatty hepatosis, then according to ICD 10, it falls under the code K76.0 (fatty degeneration of the liver).

You can learn more about the symptoms, diagnosis and treatment of hepatosis from separate materials:

Treatment of fatty liver

The treatment regimen for non-alcoholic hepatosis is to eliminate possible risk factors. If the patient is obese, then you need to try to optimize it. And start by reducing the total mass by at least 10%. Doctors recommend using minimal physical activity in parallel with dietary nutrition to achieve the goal. Limit the use of fats in the diet as much as possible. At the same time, it is worth remembering that a sharp weight loss will not only not be beneficial, it can, on the contrary, damage, aggravating the course of the disease.

For this purpose, the attending physician may prescribe thiazolidinoids in combination with biguanides, but this line of drugs has not yet been fully studied, for example, for hepatotoxicity. Metformin can help correct the process of metabolic disorders in carbohydrate metabolism.

As a result, we can confidently say that with the normalization of the daily diet, a decrease in body fat and giving up bad habits, the patient will feel better. And only in this way it is possible to fight such a disease as non-alcoholic hepatosis.

Source: http://zapechen.ru/bolezni-pecheni/gepatoz/mkb-10.html

LIVER DISEASES (K70-K77)

Included: medicinal:

  • idiosyncratic (unpredictable) liver disease
  • toxic (predictable) liver disease

Use an additional external cause code (class XX) if necessary to identify the toxic substance.

Excluded:

  • Budd-Chiari syndrome (I82.0)

Included:

  • hepatic:
    • coma NOS
    • encephalopathy NOS
  • hepatitis:
    • fulminant, not elsewhere classified, with liver failure
    • malignant, not elsewhere classified, with liver failure
  • liver (cell) necrosis with liver failure
  • yellow atrophy or liver dystrophy

Excluded:

  • alcoholic liver failure (K70.4)
  • liver failure complicating:
    • abortion, ectopic or molar pregnancy (O00-O07, O08.8)
    • pregnancy, childbirth and the puerperium (O26.6)
  • fetal and neonatal jaundice (P55-P59)
  • viral hepatitis (B15-B19)
  • associated with toxic liver damage (K71.1)

Excludes: hepatitis (chronic):

  • alcoholic (K70.1)
  • medicinal (K71.-)
  • granulomatous NEC (K75.3)
  • reactive nonspecific (K75.2)
  • viral (B15-B19)

Excluded:

  • alcoholic fibrosis of the liver (K70.2)
  • cardial sclerosis of the liver (K76.1)
  • cirrhosis of the liver):
    • alcoholic (K70.3)
    • congenital (P78.3)
  • with toxic liver damage (K71.7)

Excluded:

  • alcoholic liver disease (K70.-)
  • amyloid degeneration of the liver (E85.-)
  • cystic liver disease (congenital) (Q44.6)
  • hepatic vein thrombosis (I82.0)
  • hepatomegaly NOS (R16.0)
  • portal vein thrombosis (I81)
  • liver toxicity (K71.-)

In Russia, the International Classification of Diseases of the 10th revision (ICD-10) is adopted as a single regulatory document for accounting for morbidity, reasons for the population to apply to medical institutions of all departments, and causes of death.

ICD-10 was introduced into healthcare practice throughout the Russian Federation in 1999 by order of the Russian Ministry of Health dated May 27, 1997. №170

The publication of a new revision (ICD-11) is planned by WHO in 2017 2018.

With amendments and additions by WHO.

Processing and translation of changes © mkb-10.com

Source: http://mkb-10.com/index.php?pid=10331

Causes and treatment of fatty liver

The current pace of life entails an acute shortage of time. People snack on the go from time to time, do not devote time to a normal diet, not to mention playing sports. In response, the body periodically fails - one of the failures is fatty liver hepatosis.

Causes General characteristics of the disease

Hepatosis is a pathological deviation, formed as a result of metabolic disorders and the destruction of liver cells (hepatocytes).

In the International Classifier, each liver disease has its own code. In this case, according to microbial-10 hepatosis, the code K76.0 was assigned.

There are several factors contributing to the development of pathology. In most cases, non-alcoholic fatty liver disease (NAFLD) develops due to dietary preferences - excessive consumption of fatty foods and simple carbohydrates. To this is added a sedentary lifestyle - sedentary work, travel by transport. There is alcoholic hepatosis - the pathology develops as a result of alcoholism. There are also hereditary hepatoses. Secondary hepatosis - develops against the background of other ailments.

Causes of fatty hepatosis of the liver

Alcohol abuse. In most (up to 80% of cases) the disease affects citizens, whose day rarely goes without alcohol. For this reason, fatty hepatosis often occurs in men. Hepatosis develops in women against the background of alcoholism, the symptoms of which are hidden under alcohol intoxication. Fatty liver disease in this case is severe. It is difficult to cure fatty hepatosis of the liver against the background of alcohol, medications and a complete rejection of alcohol are needed.

Narcotic substances. It implies not only the use of heavy "chemistry", but also ordinary energy drinks and other drinks with the addition of caffeine.

Vegetarianism. Oddly enough, the victims of the disease are adherents of a plant-based diet, which, in their opinion, is the most useful and rich. In some cases, the body in a mode of constant protein deficiency fails.

Starvation. Some people resort to strict fasting in order to quickly lose weight without physical activity. A protective reaction can work in the body, and active accumulation of fat begins.

Medical hepatitis. This risk group includes people regardless of age and gender. The disease develops against the background of taking drugs that have a toxic effect on the liver.

Irrational nutrition. Long intervals between meals, frequent use of convenience foods and dishes from fast food cafes.

Diseases associated with metabolic disorders (in particular, fat metabolism). There are many cases of hepatosis development against the background of type 2 diabetes mellitus. It causes obesity not only in the liver, but also in other internal organs.

Toxic substances - car exhausts, employment in hazardous industries.

Fatty liver and pregnancy

Often, without obvious signs of liver disorder, fatty hepatosis occurs in pregnant women. The main reasons are hormonal changes and increased nutrition. It usually occurs in the third trimester, but there are exceptions. With fatty liver hepatosis, complications and even death of a woman during childbirth occur. Often accompanied by jaundice.

  • nausea;
  • vomit;
  • general weakness;
  • pain and discomfort in the liver;
  • heartburn that does not go away with a change in diet.

Symptoms should not be attributed to pregnancy and overeating. It is better to immediately report everything to the doctor for an additional examination.

Acute fatty hepatosis (toxic dystrophy)

It develops due to the active effects of toxins on the liver. The reasons are alcohol poisoning, medications in large doses, poisonous mushrooms. Unlike chronic form liver diseases, acute hepatosis develops rapidly.

Chronic hepatosis of the liver

The chronic form (hepatic steatosis) is caused by the effects of alcohol and certain diseases. Cell dystrophy can be defeated with multivitamins and hepatoprotectors.

There are degrees of hepatosis:

  • initial (zero) - small fat drops are formed in individual liver cells. The stage is non-critical, treated with diet and exercise;
  • Grade 1 - accumulations of large fat droplets are noticeable, fatty liver begins. Treatment is possible with medications and exercise;
  • 2 degrees - the area of ​​obesity is growing, but treatment and recovery is still possible;
  • 3 degrees - fatty cysts are formed. Lipocytes are actively connected with the connective tissue. An organ transplant is required. It depends on its outcome whether hepatosis of the liver can be cured at this stage. Irreversible processes begin, leading to death. The enlarged organ is easily felt on palpation.

signs

Symptoms of fatty hepatosis of the liver for a long time proceed in a latent form. Hepatosis 1 degree can be seen with the help of ultrasound.

The liver is a unique organ that lacks nerve endings. Therefore, many pathologies in the initial stages are completely asymptomatic.

In the first two stages, fatigue and general weakness appear. The patient may periodically feel discomfort in the right hypochondrium. Without taking medical measures, the second stage comes, and with it frequent bloating, heaviness after eating, heartburn. The liver can increase by 3-5 cm, which becomes noticeable during the examination. In the third stage, the patient is worried about constant nausea, pain in the stomach and right hypochondrium, frequent flatulence. Digestion is disturbed, frequent constipation or diarrhea appear.

Diagnostics

Hepatosis is treated by a gastroenterologist, an endocrinologist and a hepatologist. They find pathologies in the liver and deal with their further treatment. The first step is to rule out other liver diseases. For this, a blood, feces and urine test for bile pigments is given. The following is a list of diagnoses for which a liver examination will not be superfluous:

  • hyperinsulinemia;
  • violation of homeostasis;
  • hypothyroidism;
  • visceral abdominal obesity.

Timely diagnosis is the key to successful treatment of any disease. Various diagnostic methods identify the problem at all stages.

First, the doctor resorts to the primary examination of the patient. Palpation of the abdomen, right hypochondrium is performed. Hepatomegaly will be detected immediately.

In addition, the doctor may prescribe additional studies:

  • Ultrasound of the liver and gallbladder is effective in the initial stages of the disease, it determines the structural and morphological changes in the liver;
  • computed tomography - allows you to determine the increase in the body;
  • magnetic resonance therapy - will help determine the affected areas and the stage of the disease;
  • liver biopsy - taking a sample of liver tissue for the detection of lipocytes, helps to finally confirm the diagnosis;
  • blood test for biochemistry.

Treatment

Before starting treatment, you need to radically change your lifestyle. It is impossible to cure fatty hepatosis of the liver without changing the diet. No medicines will bring the expected result without a special diet. The basis of the diet is to control the fat in the diet. The minimum consumption of fat is due to the fact that the body must actively get rid of the fat accumulated in the liver. With the initial accumulation of lipocytes, triglycerides are easily excreted.

For patients, the doctor prescribes a treatment table No5. This is a complex of therapeutic nutrition aimed at stabilizing the patient's condition. All food is boiled or stewed. Fried foods with fatty liver hepatosis are strictly prohibited. It is a complex of a balanced amount of proteins and carbohydrates. Restriction only in the use of fats. Foods high in cholesterol, oxalic acid, seasonings and spices are also excluded.

  • vegetables, especially pumpkin, beets, carrots, all varieties of cabbage;
  • vegetable soups;
  • milk porridges and soups;
  • low-fat varieties of cheese;
  • buckwheat, rice, oatmeal on the water;
  • low-fat omelette (without the addition of spices, smoked meats, meat products);
  • boiled eggs;
  • milk;
  • kefir, fermented baked milk, curdled milk;
  • skim cheese.
  • first courses in meat broth;
  • fatty meat (lamb, pork, beef, duck);
  • oily fish;
  • tomatoes and tomato sauces;
  • radish;
  • mushrooms;
  • garlic;
  • white bread and rich pastries;
  • confectionery;
  • alcoholic drinks;
  • sausages, sausages, ham;
  • mayonnaise, ketchup and other sauces;
  • canned food;
  • pickles and marinades;
  • margarine and full fat butter
  • smoked meats;
  • fatty dairy products;
  • soda and packaged juices;
  • ice cream.

You need to eat fractionally in small portions. Drink more water, preferably at least 2 liters. From hot drinks, freshly brewed weak tea is allowed. Completely exclude coffee, cocoa, strong tea.

It should be remembered that with a neglected state of hepatosis, diet is only part of the treatment. The second component of treatment is medications. Are divided into:

  • hepatoprotectors;
  • herbal tablets;
  • sulfaamino acids.

Folk methods (addition to drug treatment, do not solve the problem on their own):

  • rosehip infusion - brew fruits, leave for several hours and drink a glass three times a day;
  • drink tea with mint;
  • drink fresh carrot juice every day;
  • drink freshly brewed green tea with lemon more often;
  • consume daily 50 grams of dried fruits (dried apricots, raisins, prunes).

To get rid of excess fat, you need not only to limit its intake into the body from the outside, but also to burn reserves. You need to devote minutes to exercise every day. Hiking in the fresh air will not be superfluous. A great addition is the refusal to use the elevator.

Possible Complications

In case of untimely detection of the disease or non-compliance with all the rules of treatment, hepatosis turns into cirrhosis, chronic hepatitis and liver failure. The above pathologies are difficult to treat and often lead to death.

Forecast

With early detection, the disease is completely curable. With the right selection of medicines and a sparing diet, the patient's condition improves after 4-6 weeks. Full recovery of the liver occurs in a few months. After completing the course of treatment, patients live a full life - work, play sports, travel, give birth to children. Enough to stick to the basics proper nutrition, do not abuse alcohol, move more - recurrence of the disease is excluded.

If hepatosis is detected at the last stage, treatment is long and difficult. If the disease has turned into cirrhosis or chronic liver failure, treatment is ineffective, 90% of cases are fatal.

Prevention

In general, the prevention of hepatosis includes a set of simple measures. Enough:

  • eat right up to 5 times a day. The intervals between meals should not exceed 3-4 hours;
  • the diet should be dominated by fruits, vegetables, herbs, low-fat dairy products;
  • limit fried, smoked, fatty, salty foods to a minimum, it is better to try to exclude them altogether;
  • do not forget about physical exercises;
  • be attentive to taking medications - take them as directed by a doctor after carefully reading the rules for taking them;
  • reduce alcohol consumption to a minimum.

In order not to worry about whether fatty hepatosis can be cured, you need to regularly undergo preventive examinations and take tests. If you experience unpleasant symptoms associated with the gastrointestinal tract, it is better to consult a doctor and start timely treatment. Timely initiated therapy can cure fatty hepatosis of the liver. An early diagnosis is the key to a successful recovery.

Source: http://pechen.org/gepatoz/zhirovoj.html

Fatty liver (K76.0)

Version: Directory of Diseases MedElement

general information

Short description

Fatty degeneration of the liver is a disease characterized by liver damage with changes similar to changes in alcoholic liver disease (fatty degeneration of hepatocytes hepatocyte is the main liver cell: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, neutralization of toxic substances and the formation of bile (Hepatocyte)

), however, with fatty degeneration of the liver, patients do not drink alcohol in quantities that can cause liver damage.

Definitions most commonly used in NAFLD:

1. Non-alcoholic fatty liver disease (NAFL). The presence of fatty degeneration of the liver without signs of damage to hepatocytes hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

in the form of balloon dystrophy or without signs of fibrosis. The risk of developing cirrhosis and liver failure is minimal.

2. Non-alcoholic steatohepatitis (NASH). The presence of liver steatosis and inflammation with damage to hepatocytes hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

(balloon dystrophy) with or without signs of fibrosis. May progress to cirrhosis, liver failure, and (rarely) liver cancer.

3. Non-alcoholic cirrhosis of the liver (NASH Cirrhosis). Presence of evidence of cirrhosis with current or previous histological evidence of steatosis or steatohepatitis.

4. Cryptogenic cirrhosis (Cryptogenic Cirrhosis) - cirrhosis without obvious etiological causes. Patients with cryptogenic cirrhosis usually have high risk factors associated with metabolic disorders such as obesity and metabolic syndrome. Increasingly, cryptogenic cirrhosis, when examined in detail, turns out to be an alcohol-associated disease.

5. Assessment of NAFLD activity (NAS). The totality of points calculated in the complex assessment of the signs of steatosis, inflammation and balloon degeneration. It is a useful tool for the semi-quantitative measurement of histological changes in liver tissue in patients with NAFLD in clinical trials.

K75.81 - Non-alcoholic steatohepatitis (NASH)

K74.0 - Fibrosis of the liver

K74.6 - Other and unspecified cirrhosis of the liver.

Classification

Types of fatty liver degeneration:

1. Macrovesicular type. The accumulation of fat in hepatocytes is local in nature and the nucleus of the hepatocyte shifts away from the center. With fatty infiltration of the liver of the macrovesicular (large-drop) type, triglycerides, as a rule, act as accumulated lipids. At the same time, the morphological criterion of fatty hepatosis is the content of triglycerides in the liver over 10% of the dry mass.

2. Microvesicular type. The accumulation of fat occurs evenly and the core remains in place. In microvesicular (fine) fatty degeneration, other (non-triglycerides) lipids (eg, free fatty acids) accumulate.

There are also focal and diffuse hepatic steatosis. The most common diffuse steatosis, which is zonal in nature (the second and third zone of the lobule).

Etiology and pathogenesis

Primary non-alcoholic fatty disease is considered as one of the manifestations of the metabolic syndrome.

Hyperinsulinism leads to activation of the synthesis of free fatty acids and triglycerides, a decrease in the rate of beta-oxidation of fatty acids in the liver and the secretion of lipids into the bloodstream. As a result, fatty degeneration of hepatocytes develops hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

The occurrence of inflammatory processes is predominantly centrilobular in nature and is associated with increased lipid peroxidation.

Of particular importance is the increased absorption of toxins from the intestines.

A sharp decrease in body weight;

Chronic protein-energy deficiency.

Inflammatory bowel disease;

Celiac Disease Celiac disease is a chronic disease caused by a lack of enzymes involved in the digestion of gluten.

Diverticulosis of the small intestine;

Microbial contamination Contamination is the entry into a certain environment of any impurity that changes the properties of this environment.

Operations on the gastrointestinal tract.

Diabetes mellitus type II;

triglyceridemia, etc.

Epidemiology

Prevalence sign: Common

Sex ratio (m/f): 0.8

The prevalence is estimated to be between 1% and 25% of the general population in various countries. In developed countries, the average level is 2-9%. Many findings are incidentally discovered during liver biopsy performed for other indications.

Most often, the disease is detected at age, although no age (except for breastfed children) excludes the diagnosis.

The sex ratio is unknown, but a female predominance is assumed.

Factors and risk groups

The high risk group includes:

more than 30% of cases is associated with the development of hepatic steatosis Hepatic steatosis is the most common hepatosis, in which fat accumulates in the liver cells

and in 20-47% with non-alcoholic steatohepatosis.

2. Persons with type 2 diabetes mellitus or impaired glucose tolerance. In 60% of patients, these conditions occur in combination with fatty degeneration, in 15% - with non-alcoholic steatohepatitis. The severity of liver damage is related to the severity of impaired glucose metabolism.

3. Persons diagnosed with hyperlipidemia, which is detected in 20-80% of patients with non-alcoholic steatohepatitis. A characteristic fact is the more frequent combination of non-alcoholic steatohepatitis with hypertriglyceridemia than with hypercholesterolemia.

4. Women of middle age.

and uncontrolled blood pressure. There is a higher prevalence of fatty liver in hypertensive patients without risk factors for developing fatty liver. The prevalence of the disease is estimated to be almost 3 times higher than in control groups matched by age and sex and keeping blood pressure at the recommended level.

Malabsorption syndrome Malabsorption syndrome (malabsorption) - a combination of hypovitaminosis, anemia and hypoproteinemia, caused by malabsorption in the small intestine

(as a consequence of the imposition of the ileojejunal Ileojejunal - relating to the ileum and jejunum.

anastomosis, extended resection of the small intestine, gastroplasty for obesity, etc.);

and some others.

Clinical picture

Clinical Criteria for Diagnosis

Symptoms, course

Most patients with non-alcoholic fatty liver disease have no complaints.

Minor discomfort in the upper right quadrant of the abdomen (about 50%);

Pain in the upper right quadrant of the abdomen (30%);

Moderate hepatosplenomegaly Hepatosplenomegaly - simultaneous significant enlargement of the liver and spleen

Arterial hypertension AH ( arterial hypertension, hypertension) - persistent increase in blood pressure from 140/90 mm Hg. and higher.

Dyslipidemia Dyslipidemia is a metabolic disorder of cholesterol and other lipids (fats), which consists in a change in their ratio in the blood

Impaired glucose tolerance.

The appearance of telangiectasia Telangiectasia is a local excessive expansion of capillaries and small vessels.

Palmar erythema Erythema - limited hyperemia (increased blood supply) of the skin

Ascites Ascites - accumulation of transudate in the abdominal cavity

Jaundice, gynecomastia Gynecomastia - an increase in the mammary glands in men

Signs of liver failure and other signs of fibrosis, cirrhosis, non-infectious hepatitis require coding in the appropriate subheadings.

Identified association with alcohol, medication, pregnancy and other etiological causes also requires coding in other subcategories.

Diagnostics

Laboratory diagnostics

are detected in 50-90% of patients, but the absence of these signs does not exclude the presence of non-alcoholic steatohepatitis (NASH).

The level of serum transaminases increased slightly - 2-4 times.

The value of the AST/ALT ratio in NASH:

Less than 1 - observed in the initial stages of the disease (for comparison, in acute alcoholic hepatitis, this ratio is usually > 2);

Equal to 1 or more - may be an indicator of more pronounced liver fibrosis;

More than 2 - is considered as an unfavorable prognostic sign.

2. In 30-60% of patients, an increase in the activity of alkaline phosphatase (usually no more than twofold) and gamma-glutamyl transpeptidase (may be isolated, not associated with an increase in alkaline phosphatase) is detected. A GGTP level > 96.5 U/L increases the risk of fibrosis.

3. In 12-17% of cases, hyperbilirubinemia occurs within% of the norm.

In clinical practice, insulin resistance is measured by the ratio of immunoreactive insulin and blood glucose levels. It should be remembered that this is a calculated indicator, which is calculated by various methods. The indicator is influenced by the level of triglycerides in the blood and race.

7. Hypertriglyceridemia occurs in 20-80% of patients with NASH.

Many patients will have low level HDL as part of the metabolic syndrome.

As the disease progresses, cholesterol levels often decrease.

It should be kept in mind that a low positive antinuclear antibody titer is not uncommon in NASH, and less than 5% of patients may have a positive low titer of antibodies to smooth muscle.

more characteristic of cirrhosis or severe fibrosis.

Unfortunately, this indicator not specific; in case of its increase, it is necessary to exclude a number of oncological diseases ( Bladder, mammary gland, etc.).

11. Comprehensive biochemical tests (BioPredictive, France):

Steato-test - allows you to identify the presence and degree of liver steatosis;

Nash test - allows you to identify NASH in patients with overweight, insulin resistance, hyperlipidemia, as well as patients with diabetes mellitus).

It is possible to use other tests for suspected non-alcoholic fibrosis or hepatitis - Fibro-test and Akti-test.

Differential Diagnosis

Complications

Fibrosis Fibrosis is an overgrowth of fibrous connective tissue that occurs, for example, as a result of inflammation.

Cirrhosis of the liver Cirrhosis of the liver is a chronic progressive disease characterized by dystrophy and necrosis of the hepatic parenchyma, accompanied by its nodular regeneration, diffuse proliferation of connective tissue and a deep restructuring of the liver architectonics.

In detail (develops especially rapidly in patients with tyrosinemia Tyrosinemia is an increased concentration of tyrosine in the blood. The disease leads to increased urinary excretion of tyrosine compounds, hepatosplenomegaly, nodular cirrhosis of the liver, multiple defects in renal tubular reabsorption and vitamin D resistant rickets. Tyrosinemia and tyrosyl excretion occur when a number of inherited (p) fermentopathies: fumarylacetoacetase deficiencies (type I), tyrosine aminotransferase (type II), 4-hydroxyphenylpyruvate hydroxylase (type III)

Almost bypassing the stage of "pure" fibrosis);

Liver failure (rarely - in parallel with the rapid formation of cirrhosis).

Treatment

Forecast

Life expectancy in non-alcoholic fatty liver disease is not lower than in healthy individuals.

Half of the patients develop progressive fibrosis, and 1/6 - cirrhosis of the liver.

Hospitalization

Prevention

1. Normalization of body weight.

2. Patients should be screened for hepatitis viruses. In the absence of viral hepatitis, they should be offered vaccination against hepatitis B and A.

Source: http://diseases.medelement.com/disease/%D0%B6%D0%B8%D1%80%D0%BE%D0%B2%D0%B0%D1%8F-%D0%B4%D0% B5%D0%B3%D0%B5%D0%BD%D0%B5%D1%80%D0%B0%D1%86%D0%B8%D1%8F-%D0%BF%D0%B5%D1%87 %D0%B5%D0%BD%D0%B8-k76-0/4827

Fatty liver disease

Description of the disease

Fatty hepatosis of the liver (liver steatosis, fatty degeneration of the liver, fatty liver) is a chronic liver disease characterized by fatty degeneration of liver cells. It occurs quite often, develops under the influence of alcohol, toxic substances (medicines), diabetes mellitus, anemia, lung diseases, severe pancreatitis and enteritis, malnutrition, obesity.

The reasons

According to the mechanism of development, hepatosis occurs due to excessive intake of fats in the liver, overload of the liver with dietary fats and carbohydrates, or due to impaired excretion of fats from the liver. Violation of the excretion of fat from the liver occurs with a decrease in the amount of substances involved in the processing of fats (protein, lipotropic factors). The formation of phospholipids, beta-lipoproteins, lecithin from fats is disrupted. And excess free fats are deposited in the liver cells.

Symptoms

Patients with hepatosis usually do not complain. The course of the disease is blurred, slowly progressing. Over time, there are constant dull pains in the right hypochondrium, nausea, vomiting, stool disorders. The patient is concerned about weakness, headache, dizziness, fatigue during exercise. Very rarely, hepatosis is observed with a pronounced clinical picture: severe pain, weight loss, itching, bloating. On examination, an enlarged, slightly painful liver is found. The course of the disease is usually not severe, but sometimes fatty hepatosis can turn into chronic hepatitis or cirrhosis of the liver.

Diagnostics

With ultrasound of the abdominal cavity - an increase in the echogenicity of the liver, an increase in its size. AT biochemical research blood, a slight increase in the activity of liver tests and changes in protein fractions.

Treatment

First of all, one should either eliminate or minimize the effect of the factor that led to the deposition of fat in the liver. This is almost always possible in relation to alcohol, if it is not about the formation of dependence, when the help of a narcologist is required. Patients with diabetes mellitus and hyperlipidemia should be observed jointly by an endocrinologist and a cardiologist, respectively. All patients require a low-fat diet and sufficient daily physical activity.

In obese patients, doctors usually consider it necessary to reduce the patient's body weight. The effect of weight loss on the course of fatty hepatosis is ambiguous. Rapid weight loss naturally leads to an increase in inflammation activity and progression of fibrosis. Reducing the weight nakg/year positively affects the severity of steatosis, inflammation and the degree of liver fibrosis. The most effective weight loss is considered to be no more than 1.6 kg / week, which is achieved with a daily caloric intake of 25 cal / kg / day.

Fatty hepatosis of the liver in the ICD classification:

Hello! Which doctor should I contact for treatment for a diagnosis of cirrhosis of the liver?

Which doctors should I contact if fatty hepatosis of the liver occurs:

Good afternoon. I am 67 years old, height 158 ​​cm, weight 78 kg. I started gaining weight after the death of my husband. I do not abuse alcohol. I walk moderately. What should I do? The analyzes are normal - and the ultrasound diagnosis: echo-signs of fatty hepatosis, chronic cholecystitis, chronic pancreatitis. What to do?

Source: http://med36.com/ill/428

Fatty hepatosis

Liver problems have always been a big concern for many people. Indeed, if this important organ is out of order, then you can forget about the normal functioning of the whole organism. Yes, and the activity of the person himself turns out to be practically stopped until he begins the correct treatment of his illness.

Many believe that liver problems are the result of a poor lifestyle or alcohol abuse. Often this is true, but there are still other reasons that affect the appearance of liver diseases. Diseases such as fatty liver can also occur due to completely different factors, which we will talk about.

What is fatty liver disease?

Under fatty hepatosis (another name is non-alcoholic steatohepatitis) is understood a certain process, as a result of which a fatty layer begins to form in the liver cells. Moreover, there is a picture when fat cells begin to completely replace healthy liver cells, which is a consequence of the accumulation of simple fats in healthy cells of the organ.

According to the ICD-10, fatty liver disease has the code K 76 and the name "fatty liver degeneration".

The liver performs the function of processing various toxins that are formed as a result of the use of alcoholic beverages and medicines. The body converts all these components into simple fats, but any person is already prone to eating fatty foods, so there is an excess of fat in the liver cells. It is at this moment that the accumulation of fat cells in the liver occurs, which leads to the appearance of the disease.

Ignoring the treatment process, fat cells begin to accumulate, forming a full-fledged adipose tissue on the surface of the liver. Naturally, such a layer of fat prevents the body from performing its protective functions, leaving the body alone with various harmful toxins and similar substances.

The danger of such a disease as fatty hepatosis lies in the possibility of developing into more serious diseases - fibrosis and cirrhosis of the liver, and this is an immediate threat to human life.

To avoid this, it is necessary to diagnose the disease in a timely manner. At the first signs of the disease, you should contact the specialized specialists - an endocrinologist or a hepatologist. At the same time, the endocrinologist is responsible for treating the causes that led to the appearance of the disease, and the hepatologist treats the liver damage itself directly.

The reasons

For the correct preparation of the treatment regimen, it is necessary to find out which cause was the result of the occurrence of fatty hepatosis. Below are the most likely factors that directly affect the formation of fat cells, as well as their replacement of healthy ones:

  1. If a person is diagnosed with diseases in which fat metabolism is impaired. These include obesity, type 2 diabetes, and if a person has an elevated level of lipids in the blood.
  2. The effect of toxins on the body. The liver copes well with various kinds of toxins that enter the body along with certain foods and alcohol, but if this exposure is regular and intense, then the organ simply ceases to cope with the load. In particular, if a person regularly consumes alcohol, then he may develop alcoholic fatty hepatosis.
  3. If settlements are located near radioactive waste disposal sites, then there is a high risk of fatty liver among its inhabitants.
  4. Wrong food intake. If a person eats irregularly, there is not enough protein in his diet, then this disrupts the process of lipid metabolism. In addition, lovers of a beautiful figure who exhaust themselves with strict diets and starvation can also be included here. As a result of these actions, the body is depleted, which leads to the appearance of the disease.
  5. Wrong work digestive system can also be a consequence of the appearance of fatty hepatosis.
  6. Antibiotics solve many problems, but they can also harm. Especially if the course of treatment is long, and at the end of it, restorative therapy in the form of taking probiotics was not carried out.
  7. Various endocrine diseases, which are expressed in the lack of thyroxin - a hormone thyroid gland, or excessive influence of cortisol, aldosterone and other hormones of the adrenal cortex.
  8. Of particular danger is fatty hepatosis during pregnancy, because there is a real risk to the fetus. At the same time, hepatosis is considered a disease of a hereditary nature, so it can be transmitted from mother to her child.

Under the hour of pregnancy in the body of a woman, an increased formation of estrogens is observed, which leads to the occurrence of cholestasis. Hepatosis itself begins to develop against the background of active bile secretion into the blood. Experts note that fatty hepatosis occurs in those women who have previously suffered from any liver disease.

Varieties of the disease

The types of the disease differ in the degree of accumulation of fat cells. To date, there are several stages:

On the organ there is a single or multiple accumulation of fat cells. Against their background, diffuse fatty hepatosis may develop.

  • Second degree

    With this form, the area of ​​​​fat accumulations increases, and connective tissue begins to form between the cells.

  • Third degree

    On the organ, connective tissue is already pronounced, which ends with fibroblasts. There is also a large accumulation of fat on the liver.

  • Symptoms

    Fatty hepatosis does not manifest itself immediately, so it is quite difficult to diagnose it at an early stage. It takes a certain amount of time before fat cells begin to take out healthy liver cells. Symptoms are most pronounced in the third degree, but it is better not to bring it up to this point, because in this case only a transplant of a healthy organ will help.

    Here is a list of the main symptoms:

    • vomit;
    • gagging;
    • blurred vision;
    • dysbacteriosis;
    • in the area of ​​​​the liver, a person begins to feel a feeling of heaviness;
    • dull skin tone.

    The insidiousness of this disease lies in the fact that these symptoms are not very pronounced, so a person quite often ignores them, believing that he just ate something wrong. Therefore, doctors advise not to be negligent to your health, but to contact specialists even with minor complaints and symptoms.

    Diagnostics

    If a patient goes to a specialist with the above symptoms, then the doctor should prescribe one of the following examinations:

    1. Ultrasound examination, which should show echoes of the disease.

    As a rule, ultrasound is enough for the timely diagnosis of fatty hepatosis. Even minor diffuse changes in the liver can be a cause for concern. To identify them, the following diagnostics are carried out:

    • Clinical and biochemical analysis of blood.
    • Echography.
    • Analysis of urine.
    • Ultrasound procedure.

    medical treatment

    The treatment of fatty hepatosis is a combination of many actions, among many of which, as a technique medical preparations, as well as a certain diet aimed at abandoning negative habits.

    Now Lopid, Troglitatazone and Actigall are used as medicines for this disease. In principle, all therapy should be based on the following factors:

    • Taking medications that normalize blood circulation.
    • Insulin medications.
    • Lipid balancing drugs.
    • Proper nutrition.

    In this video you will see clearly what happens to the liver during illness and how to cope with the disease.

    Treatment at home

    But apart from traditional medicine, there is also a folk one, which also turns out to be very effective in the treatment of fatty hepatosis. Many experts point out that it is the treatment folk remedies allows you to get rid of this disease. The essence of this treatment is to take various decoctions that cleanse the liver.

    Here are some actionable recipes.

    If a person has an enlarged liver against the background of fatty hepatosis, then you can try the following recipe:

    • We take a few lemons, which we previously washed.
    • We grind them together with the peel in a blender, or pass through a meat grinder.
    • We take half a liter of boiling water and pour the resulting slurry of lemons, then leave it overnight.
    • The next day, it is necessary to strain the broth, and then take it during the day immediately before meals.
    • Remember that you can drink the infusion only three days in a row.

    In this video, even more recipes and methods of dealing with the disease.

    Diet

    Fatty hepatosis is a specific disease, which can be eliminated only if a person completely changes his lifestyle. We have already talked about giving up alcohol, but we will also have to normalize nutrition by following the right diet. Its basis is to minimize the amount of fat entering the body, so the steaming or boiling method should be used for cooking.

    • fatty meat broths;
    • meat and fish containing a large amount of fat;
    • garlic and onions;
    • legumes;
    • mushrooms;
    • tomatoes;
    • various kinds of canned products;
    • radish;
    • fatty sour cream and also cottage cheese;
    • smoked meats and pickles;
    • all carbonated drinks, coffee and cocoa should be deleted from the menu. You can replace them with green tea without sugar.

    As for allowed products, there are also several of them:

    • vegetables in any form, except stewed and fried;
    • milk soup;
    • soups and broths without meat;
    • low-fat cheese;
    • steamed omelet;
    • one boiled egg per day.
    • dairy products with low fat content;
    • various kinds of cereals from rice, oats, buckwheat, semolina, etc.;
    • you need to include any greens in the diet: parsley, dill, etc. They help to remove excess fats from the body, and they are very effective for preventive purposes;
    • you still need to eat the following foods: rice bran, apricot pits, watermelon, pumpkin, brewer's yeast, etc.
    • you should also include dried fruits in your daily diet: about 25 grams per day.

    Attention! You must understand that taking medications alone will not give the desired result. Only complex therapy based on a strict diet will help remove accumulated toxins and fats from the body.

    Watch this video for preventive measures.

    Fatty liver disease is not a disease that cannot be cured. If you do not run it to the extreme stage, when only a liver transplant can help, then you can get rid of this problem with the usual folk remedies and the right diet. Of course, you will have to give up the usual dishes and pleasures, but when the question of health arises, then other moments should be put on the back burner.

    At the initial stage of development, fat accumulates in hepatocytes, which over time simply leads to dystrophy of the liver cells.

    If the disease is not diagnosed at an early stage and appropriate therapy is not carried out, then irreversible inflammatory changes occur in the parenchyma, which lead to the development of tissue necrosis. If fatty liver is not treated, it can develop into cirrhosis, which is no longer treatable. In the article, we will consider the reason for the development of the disease, methods of its treatment and classification according to ICD-10.

    Causes of fatty liver and its prevalence

    The causes of the development of the disease have not yet been exactly proven, but factors are known that can surely provoke the onset of this disease. These include:

    • completeness;
    • diabetes;
    • violation of metabolic processes (lipid);
    • minimal physical activity with a nutritious daily diet high in fat.

    Most cases of development of fatty hepatosis are recorded by physicians in developed countries with above-average living standards.

    There are a number of other factors associated with hormonal disruptions, such as insulin resistance and the presence of sugar in the blood. You can not omit the hereditary factor, it also plays a big role. But still, the main reason is malnutrition, a sedentary lifestyle and excess weight. All causes are in no way related to the intake of alcoholic beverages, so fatty hepatosis is often called non-alcoholic. But if alcohol addiction is added to the above reasons, then fatty hepatosis will develop many times faster.

    In medicine, it is very convenient to use the coding of diseases to systematize them. It is even easier to indicate a diagnosis on a sick leave using a code. Codes for all diseases are presented in the International Classification of Diseases, Injuries and Various Health Problems. The tenth revision is currently in effect.

    All liver diseases according to the International Classification of the Tenth Revision are encrypted under the codes K70-K77. And if we talk about fatty hepatosis, then according to ICD 10, it falls under the code K76.0 (fatty degeneration of the liver).

    You can learn more about the symptoms, diagnosis and treatment of hepatosis from separate materials:

    Treatment of fatty liver

    The treatment regimen for non-alcoholic hepatosis is to eliminate possible risk factors. If the patient is obese, then you need to try to optimize it. And start by reducing the total mass by at least 10%. Doctors recommend using minimal physical activity in parallel with dietary nutrition to achieve the goal. Limit the use of fats in the diet as much as possible. At the same time, it is worth remembering that a sharp weight loss will not only not be beneficial, it can, on the contrary, damage, aggravating the course of the disease.

    For this purpose, the attending physician may prescribe thiazolidinoids in combination with biguanides, but this line of drugs has not yet been fully studied, for example, for hepatotoxicity. Metformin can help correct the process of metabolic disorders in carbohydrate metabolism.

    As a result, we can confidently say that with the normalization of the daily diet, a decrease in body fat and giving up bad habits, the patient will feel better. And only in this way it is possible to fight such a disease as non-alcoholic hepatosis.

    LIVER DISEASES (K70-K77)

    Included: medicinal:

    • idiosyncratic (unpredictable) liver disease
    • toxic (predictable) liver disease

    Use an additional external cause code (class XX) if necessary to identify the toxic substance.

    Excluded:

    • Budd-Chiari syndrome (I82.0)

    Included:

    • hepatic:
      • coma NOS
      • encephalopathy NOS
    • hepatitis:
      • fulminant, not elsewhere classified, with liver failure
      • malignant, not elsewhere classified, with liver failure
    • liver (cell) necrosis with liver failure
    • yellow atrophy or liver dystrophy

    Excluded:

    • alcoholic liver failure (K70.4)
    • liver failure complicating:
      • abortion, ectopic or molar pregnancy (O00-O07, O08.8)
      • pregnancy, childbirth and the puerperium (O26.6)
    • fetal and neonatal jaundice (P55-P59)
    • viral hepatitis (B15-B19)
    • associated with toxic liver damage (K71.1)

    Excludes: hepatitis (chronic):

    • alcoholic (K70.1)
    • medicinal (K71.-)
    • granulomatous NEC (K75.3)
    • reactive nonspecific (K75.2)
    • viral (B15-B19)

    Excluded:

    • alcoholic fibrosis of the liver (K70.2)
    • cardial sclerosis of the liver (K76.1)
    • cirrhosis of the liver):
      • alcoholic (K70.3)
      • congenital (P78.3)
    • with toxic liver damage (K71.7)

    Excluded:

    • alcoholic liver disease (K70.-)
    • amyloid degeneration of the liver (E85.-)
    • cystic liver disease (congenital) (Q44.6)
    • hepatic vein thrombosis (I82.0)
    • hepatomegaly NOS (R16.0)
    • portal vein thrombosis (I81)
    • liver toxicity (K71.-)

    In Russia, the International Classification of Diseases of the 10th revision (ICD-10) is adopted as a single regulatory document for accounting for morbidity, reasons for the population to apply to medical institutions of all departments, and causes of death.

    ICD-10 was introduced into healthcare practice throughout the Russian Federation in 1999 by order of the Russian Ministry of Health dated May 27, 1997. №170

    The publication of a new revision (ICD-11) is planned by WHO in 2017 2018.

    With amendments and additions by WHO.

    Processing and translation of changes © mkb-10.com

    Causes and treatment of fatty liver

    The current pace of life entails an acute shortage of time. People snack on the go from time to time, do not devote time to a normal diet, not to mention playing sports. In response, the body periodically fails - one of the failures is fatty liver hepatosis.

    Causes General characteristics of the disease

    Hepatosis is a pathological deviation, formed as a result of metabolic disorders and the destruction of liver cells (hepatocytes).

    In the International Classifier, each liver disease has its own code. In this case, according to microbial-10 hepatosis, the code K76.0 was assigned.

    There are several factors contributing to the development of pathology. In most cases, non-alcoholic fatty liver disease (NAFLD) develops due to dietary preferences - excessive consumption of fatty foods and simple carbohydrates. To this is added a sedentary lifestyle - sedentary work, travel by transport. There is alcoholic hepatosis - the pathology develops as a result of alcoholism. There are also hereditary hepatoses. Secondary hepatosis - develops against the background of other ailments.

    Causes of fatty hepatosis of the liver

    Alcohol abuse. In most (up to 80% of cases) the disease affects citizens, whose day rarely goes without alcohol. For this reason, fatty hepatosis often occurs in men. Hepatosis develops in women against the background of alcoholism, the symptoms of which are hidden under alcohol intoxication. Fatty liver disease in this case is severe. It is difficult to cure fatty hepatosis of the liver against the background of alcohol, medications and a complete rejection of alcohol are needed.

    Narcotic substances. It implies not only the use of heavy "chemistry", but also ordinary energy drinks and other drinks with the addition of caffeine.

    Vegetarianism. Oddly enough, the victims of the disease are adherents of a plant-based diet, which, in their opinion, is the most useful and rich. In some cases, the body in a mode of constant protein deficiency fails.

    Starvation. Some people resort to strict fasting in order to quickly lose weight without physical activity. A protective reaction can work in the body, and active accumulation of fat begins.

    Medical hepatitis. This risk group includes people regardless of age and gender. The disease develops against the background of taking drugs that have a toxic effect on the liver.

    Irrational nutrition. Long intervals between meals, frequent use of convenience foods and dishes from fast food cafes.

    Diseases associated with metabolic disorders (in particular, fat metabolism). There are many cases of hepatosis development against the background of type 2 diabetes mellitus. It causes obesity not only in the liver, but also in other internal organs.

    Toxic substances - car exhausts, employment in hazardous industries.

    Fatty liver and pregnancy

    Often, without obvious signs of liver disorder, fatty hepatosis occurs in pregnant women. The main reasons are hormonal changes and increased nutrition. It usually occurs in the third trimester, but there are exceptions. With fatty liver hepatosis, complications and even death of a woman during childbirth occur. Often accompanied by jaundice.

    • nausea;
    • vomit;
    • general weakness;
    • pain and discomfort in the liver;
    • heartburn that does not go away with a change in diet.

    Symptoms should not be attributed to pregnancy and overeating. It is better to immediately report everything to the doctor for an additional examination.

    Acute fatty hepatosis (toxic dystrophy)

    It develops due to the active effects of toxins on the liver. The reasons are alcohol poisoning, medications in large doses, poisonous mushrooms. Unlike the chronic form of liver disease, acute hepatosis develops rapidly.

    Chronic hepatosis of the liver

    The chronic form (hepatic steatosis) is caused by the effects of alcohol and certain diseases. Cell dystrophy can be defeated with multivitamins and hepatoprotectors.

    There are degrees of hepatosis:

    • initial (zero) - small fat drops are formed in individual liver cells. The stage is non-critical, treated with diet and exercise;
    • Grade 1 - accumulations of large fat droplets are noticeable, fatty liver begins. Treatment is possible with medications and exercise;
    • 2 degrees - the area of ​​obesity is growing, but treatment and recovery is still possible;
    • 3 degrees - fatty cysts are formed. Lipocytes are actively connected with the connective tissue. An organ transplant is required. It depends on its outcome whether hepatosis of the liver can be cured at this stage. Irreversible processes begin, leading to death. The enlarged organ is easily felt on palpation.

    signs

    Symptoms of fatty hepatosis of the liver for a long time proceed in a latent form. Hepatosis 1 degree can be seen with the help of ultrasound.

    The liver is a unique organ that lacks nerve endings. Therefore, many pathologies in the initial stages are completely asymptomatic.

    In the first two stages, fatigue and general weakness appear. The patient may periodically feel discomfort in the right hypochondrium. Without taking medical measures, the second stage comes, and with it frequent bloating, heaviness after eating, heartburn. The liver can increase by 3-5 cm, which becomes noticeable during the examination. In the third stage, the patient is worried about constant nausea, pain in the stomach and right hypochondrium, frequent flatulence. Digestion is disturbed, frequent constipation or diarrhea appear.

    Diagnostics

    Hepatosis is treated by a gastroenterologist, an endocrinologist and a hepatologist. They find pathologies in the liver and deal with their further treatment. The first step is to rule out other liver diseases. For this, a blood, feces and urine test for bile pigments is given. The following is a list of diagnoses for which a liver examination will not be superfluous:

    • hyperinsulinemia;
    • violation of homeostasis;
    • hypothyroidism;
    • visceral abdominal obesity.

    Timely diagnosis is the key to successful treatment of any disease. Various diagnostic methods identify the problem at all stages.

    First, the doctor resorts to the primary examination of the patient. Palpation of the abdomen, right hypochondrium is performed. Hepatomegaly will be detected immediately.

    In addition, the doctor may prescribe additional studies:

    • Ultrasound of the liver and gallbladder is effective in the initial stages of the disease, it determines the structural and morphological changes in the liver;
    • computed tomography - allows you to determine the increase in the body;
    • magnetic resonance therapy - will help determine the affected areas and the stage of the disease;
    • liver biopsy - taking a sample of liver tissue for the detection of lipocytes, helps to finally confirm the diagnosis;
    • blood test for biochemistry.

    Treatment

    Before starting treatment, you need to radically change your lifestyle. It is impossible to cure fatty hepatosis of the liver without changing the diet. No medicines will bring the expected result without a special diet. The basis of the diet is to control the fat in the diet. The minimum consumption of fat is due to the fact that the body must actively get rid of the fat accumulated in the liver. With the initial accumulation of lipocytes, triglycerides are easily excreted.

    For patients, the doctor prescribes a treatment table No5. This is a complex of therapeutic nutrition aimed at stabilizing the patient's condition. All food is boiled or stewed. Fried foods with fatty liver hepatosis are strictly prohibited. It is a complex of a balanced amount of proteins and carbohydrates. Restriction only in the use of fats. Foods high in cholesterol, oxalic acid, seasonings and spices are also excluded.

    • vegetables, especially pumpkin, beets, carrots, all varieties of cabbage;
    • vegetable soups;
    • milk porridges and soups;
    • low-fat varieties of cheese;
    • buckwheat, rice, oatmeal on the water;
    • low-fat omelette (without the addition of spices, smoked meats, meat products);
    • boiled eggs;
    • milk;
    • kefir, fermented baked milk, curdled milk;
    • skim cheese.
    • first courses in meat broth;
    • fatty meat (lamb, pork, beef, duck);
    • oily fish;
    • tomatoes and tomato sauces;
    • radish;
    • mushrooms;
    • garlic;
    • white bread and rich pastries;
    • confectionery;
    • alcoholic drinks;
    • sausages, sausages, ham;
    • mayonnaise, ketchup and other sauces;
    • canned food;
    • pickles and marinades;
    • margarine and full fat butter
    • smoked meats;
    • fatty dairy products;
    • soda and packaged juices;
    • ice cream.

    You need to eat fractionally in small portions. Drink more water, preferably at least 2 liters. From hot drinks, freshly brewed weak tea is allowed. Completely exclude coffee, cocoa, strong tea.

    It should be remembered that with a neglected state of hepatosis, diet is only part of the treatment. The second component of treatment is medications. Are divided into:

    • hepatoprotectors;
    • herbal tablets;
    • sulfaamino acids.

    Alternative methods (addition to drug treatment, they do not solve the problem on their own):

    • rosehip infusion - brew fruits, leave for several hours and drink a glass three times a day;
    • drink tea with mint;
    • drink fresh carrot juice every day;
    • drink freshly brewed green tea with lemon more often;
    • consume daily 50 grams of dried fruits (dried apricots, raisins, prunes).

    To get rid of excess fat, you need not only to limit its intake into the body from the outside, but also to burn reserves. You need to devote minutes to exercise every day. Hiking in the fresh air will not be superfluous. A great addition is the refusal to use the elevator.

    Possible Complications

    In case of untimely detection of the disease or non-compliance with all the rules of treatment, hepatosis turns into cirrhosis, chronic hepatitis and liver failure. The above pathologies are difficult to treat and often lead to death.

    Forecast

    With early detection, the disease is completely curable. With the right selection of medicines and a sparing diet, the patient's condition improves after 4-6 weeks. Full recovery of the liver occurs in a few months. After completing the course of treatment, patients live a full life - work, play sports, travel, give birth to children. It is enough to adhere to the basics of proper nutrition, not to abuse alcohol, to move more - a recurrence of the disease is excluded.

    If hepatosis is detected at the last stage, treatment is long and difficult. If the disease has turned into cirrhosis or chronic liver failure, treatment is ineffective, 90% of cases are fatal.

    Prevention

    In general, the prevention of hepatosis includes a set of simple measures. Enough:

    • eat right up to 5 times a day. The intervals between meals should not exceed 3-4 hours;
    • the diet should be dominated by fruits, vegetables, herbs, low-fat dairy products;
    • limit fried, smoked, fatty, salty foods to a minimum, it is better to try to exclude them altogether;
    • do not forget about physical exercises;
    • be attentive to taking medications - take them as directed by a doctor after carefully reading the rules for taking them;
    • reduce alcohol consumption to a minimum.

    In order not to worry about whether fatty hepatosis can be cured, you need to regularly undergo preventive examinations and take tests. If you experience unpleasant symptoms associated with the gastrointestinal tract, it is better to consult a doctor and start timely treatment. Timely initiated therapy can cure fatty hepatosis of the liver. An early diagnosis is the key to a successful recovery.

    Fatty liver (K76.0)

    Version: Directory of Diseases MedElement

    general information

    Short description

    Fatty degeneration of the liver is a disease characterized by liver damage with changes similar to changes in alcoholic liver disease (fatty degeneration of hepatocytes hepatocyte is the main liver cell: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, neutralization of toxic substances and the formation of bile (Hepatocyte)

    ), however, with fatty degeneration of the liver, patients do not drink alcohol in quantities that can cause liver damage.

    Definitions most commonly used in NAFLD:

    1. Non-alcoholic fatty liver disease (NAFL). The presence of fatty degeneration of the liver without signs of damage to hepatocytes hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

    in the form of balloon dystrophy or without signs of fibrosis. The risk of developing cirrhosis and liver failure is minimal.

    2. Non-alcoholic steatohepatitis (NASH). The presence of liver steatosis and inflammation with damage to hepatocytes hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

    (balloon dystrophy) with or without signs of fibrosis. May progress to cirrhosis, liver failure, and (rarely) liver cancer.

    3. Non-alcoholic cirrhosis of the liver (NASH Cirrhosis). Presence of evidence of cirrhosis with current or previous histological evidence of steatosis or steatohepatitis.

    4. Cryptogenic cirrhosis (Cryptogenic Cirrhosis) - cirrhosis without obvious etiological causes. Patients with cryptogenic cirrhosis usually have high risk factors associated with metabolic disorders such as obesity and metabolic syndrome. Increasingly, cryptogenic cirrhosis, when examined in detail, turns out to be an alcohol-associated disease.

    5. Assessment of NAFLD activity (NAS). The totality of points calculated in the complex assessment of the signs of steatosis, inflammation and balloon degeneration. It is a useful tool for the semi-quantitative measurement of histological changes in liver tissue in patients with NAFLD in clinical trials.

    K75.81 - Non-alcoholic steatohepatitis (NASH)

    K74.0 - Fibrosis of the liver

    K74.6 - Other and unspecified cirrhosis of the liver.

    Classification

    Types of fatty liver degeneration:

    1. Macrovesicular type. The accumulation of fat in hepatocytes is local in nature and the nucleus of the hepatocyte shifts away from the center. With fatty infiltration of the liver of the macrovesicular (large-drop) type, triglycerides, as a rule, act as accumulated lipids. At the same time, the morphological criterion of fatty hepatosis is the content of triglycerides in the liver over 10% of the dry mass.

    2. Microvesicular type. The accumulation of fat occurs evenly and the core remains in place. In microvesicular (fine) fatty degeneration, other (non-triglycerides) lipids (eg, free fatty acids) accumulate.

    There are also focal and diffuse hepatic steatosis. The most common diffuse steatosis, which is zonal in nature (the second and third zone of the lobule).

    Etiology and pathogenesis

    Primary non-alcoholic fatty disease is considered as one of the manifestations of the metabolic syndrome.

    Hyperinsulinism leads to activation of the synthesis of free fatty acids and triglycerides, a decrease in the rate of beta-oxidation of fatty acids in the liver and the secretion of lipids into the bloodstream. As a result, fatty degeneration of hepatocytes develops hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

    The occurrence of inflammatory processes is predominantly centrilobular in nature and is associated with increased lipid peroxidation.

    Of particular importance is the increased absorption of toxins from the intestines.

    A sharp decrease in body weight;

    Chronic protein-energy deficiency.

    Inflammatory bowel disease;

    Celiac Disease Celiac disease is a chronic disease caused by a lack of enzymes involved in the digestion of gluten.

    Diverticulosis of the small intestine;

    Microbial contamination Contamination is the entry into a certain environment of any impurity that changes the properties of this environment.

    Operations on the gastrointestinal tract.

    Diabetes mellitus type II;

    triglyceridemia, etc.

    Epidemiology

    Prevalence sign: Common

    Sex ratio (m/f): 0.8

    The prevalence is estimated to be between 1% and 25% of the general population in various countries. In developed countries, the average level is 2-9%. Many findings are incidentally discovered during liver biopsy performed for other indications.

    Most often, the disease is detected at age, although no age (except for breastfed children) excludes the diagnosis.

    The sex ratio is unknown, but a female predominance is assumed.

    Factors and risk groups

    The high risk group includes:

    more than 30% of cases is associated with the development of hepatic steatosis Hepatic steatosis is the most common hepatosis, in which fat accumulates in the liver cells

    and in 20-47% with non-alcoholic steatohepatosis.

    2. Persons with type 2 diabetes mellitus or impaired glucose tolerance. In 60% of patients, these conditions occur in combination with fatty degeneration, in 15% - with non-alcoholic steatohepatitis. The severity of liver damage is related to the severity of impaired glucose metabolism.

    3. Persons diagnosed with hyperlipidemia, which is detected in 20-80% of patients with non-alcoholic steatohepatitis. A characteristic fact is the more frequent combination of non-alcoholic steatohepatitis with hypertriglyceridemia than with hypercholesterolemia.

    4. Women of middle age.

    and uncontrolled blood pressure. There is a higher prevalence of fatty liver in hypertensive patients without risk factors for developing fatty liver. The prevalence of the disease is estimated to be almost 3 times higher than in control groups matched by age and sex and keeping blood pressure at the recommended level.

    Malabsorption syndrome Malabsorption syndrome (malabsorption) - a combination of hypovitaminosis, anemia and hypoproteinemia, caused by malabsorption in the small intestine

    (as a consequence of the imposition of the ileojejunal Ileojejunal - relating to the ileum and jejunum.

    anastomosis, extended resection of the small intestine, gastroplasty for obesity, etc.);

    and some others.

    Clinical picture

    Clinical Criteria for Diagnosis

    Symptoms, course

    Most patients with non-alcoholic fatty liver disease have no complaints.

    Minor discomfort in the upper right quadrant of the abdomen (about 50%);

    Pain in the upper right quadrant of the abdomen (30%);

    Moderate hepatosplenomegaly Hepatosplenomegaly - simultaneous significant enlargement of the liver and spleen

    Arterial hypertension AG (arterial hypertension, hypertension) - persistent increase in blood pressure from 140/90 mm Hg. and higher.

    Dyslipidemia Dyslipidemia is a metabolic disorder of cholesterol and other lipids (fats), which consists in a change in their ratio in the blood

    Impaired glucose tolerance.

    The appearance of telangiectasia Telangiectasia is a local excessive expansion of capillaries and small vessels.

    Palmar erythema Erythema - limited hyperemia (increased blood supply) of the skin

    Ascites Ascites - accumulation of transudate in the abdominal cavity

    Jaundice, gynecomastia Gynecomastia - an increase in the mammary glands in men

    Signs of liver failure and other signs of fibrosis, cirrhosis, non-infectious hepatitis require coding in the appropriate subheadings.

    Identified association with alcohol, medication, pregnancy and other etiological causes also requires coding in other subcategories.

    Diagnostics

    Laboratory diagnostics

    are detected in 50-90% of patients, but the absence of these signs does not exclude the presence of non-alcoholic steatohepatitis (NASH).

    The level of serum transaminases increased slightly - 2-4 times.

    The value of the AST/ALT ratio in NASH:

    Less than 1 - observed in the initial stages of the disease (for comparison, in acute alcoholic hepatitis, this ratio is usually > 2);

    Equal to 1 or more - may be an indicator of more pronounced liver fibrosis;

    More than 2 - is considered as an unfavorable prognostic sign.

    2. In 30-60% of patients, an increase in the activity of alkaline phosphatase (usually no more than twofold) and gamma-glutamyl transpeptidase (may be isolated, not associated with an increase in alkaline phosphatase) is detected. A GGTP level > 96.5 U/L increases the risk of fibrosis.

    3. In 12-17% of cases, hyperbilirubinemia occurs within% of the norm.

    In clinical practice, insulin resistance is measured by the ratio of immunoreactive insulin and blood glucose levels. It should be remembered that this is a calculated indicator, which is calculated by various methods. The indicator is influenced by the level of triglycerides in the blood and race.

    7. Hypertriglyceridemia occurs in 20-80% of patients with NASH.

    Many patients will have low HDL as part of the metabolic syndrome.

    As the disease progresses, cholesterol levels often decrease.

    It should be kept in mind that a low positive antinuclear antibody titer is not uncommon in NASH, and less than 5% of patients may have a positive low titer of antibodies to smooth muscle.

    more characteristic of cirrhosis or severe fibrosis.

    Unfortunately, this indicator is not specific; in case of its increase, it is necessary to exclude a number of oncological diseases (bladder, breast, etc.).

    11. Comprehensive biochemical tests (BioPredictive, France):

    Steato-test - allows you to identify the presence and degree of liver steatosis;

    Nash test - allows you to identify NASH in patients with overweight, insulin resistance, hyperlipidemia, as well as patients with diabetes mellitus).

    It is possible to use other tests for suspected non-alcoholic fibrosis or hepatitis - Fibro-test and Akti-test.

    Differential Diagnosis

    Complications

    Fibrosis Fibrosis is an overgrowth of fibrous connective tissue that occurs, for example, as a result of inflammation.

    Cirrhosis of the liver Cirrhosis of the liver is a chronic progressive disease characterized by dystrophy and necrosis of the hepatic parenchyma, accompanied by its nodular regeneration, diffuse proliferation of connective tissue and a deep restructuring of the liver architectonics.

    In detail (develops especially rapidly in patients with tyrosinemia Tyrosinemia is an increased concentration of tyrosine in the blood. The disease leads to increased urinary excretion of tyrosine compounds, hepatosplenomegaly, nodular cirrhosis of the liver, multiple defects in renal tubular reabsorption and vitamin D resistant rickets. Tyrosinemia and tyrosyl excretion occur when a number of inherited (p) fermentopathies: fumarylacetoacetase deficiencies (type I), tyrosine aminotransferase (type II), 4-hydroxyphenylpyruvate hydroxylase (type III)

    Practically bypassing the stage of "pure" fibrosis);

    Liver failure (rarely - in parallel with the rapid formation of cirrhosis).

    Treatment

    Forecast

    Life expectancy in non-alcoholic fatty liver disease is not lower than in healthy individuals.

    Half of the patients develop progressive fibrosis, and 1/6 - cirrhosis of the liver.

    Hospitalization

    Prevention

    1. Normalization of body weight.

    2. Patients should be screened for hepatitis viruses. In the absence of viral hepatitis, they should be offered vaccination against hepatitis B and A.

    Fatty liver disease

    Description of the disease

    Fatty hepatosis of the liver (liver steatosis, fatty degeneration of the liver, fatty liver) is a chronic liver disease characterized by fatty degeneration of liver cells. It occurs quite often, develops under the influence of alcohol, toxic substances (medicines), diabetes mellitus, anemia, lung diseases, severe pancreatitis and enteritis, malnutrition, obesity.

    The reasons

    According to the mechanism of development, hepatosis occurs due to excessive intake of fats in the liver, overload of the liver with dietary fats and carbohydrates, or due to impaired excretion of fats from the liver. Violation of the excretion of fat from the liver occurs with a decrease in the amount of substances involved in the processing of fats (protein, lipotropic factors). The formation of phospholipids, beta-lipoproteins, lecithin from fats is disrupted. And excess free fats are deposited in the liver cells.

    Symptoms

    Patients with hepatosis usually do not complain. The course of the disease is blurred, slowly progressing. Over time, there are constant dull pains in the right hypochondrium, nausea, vomiting, stool disorders. The patient is concerned about weakness, headache, dizziness, fatigue during exercise. Very rarely, hepatosis is observed with a pronounced clinical picture: severe pain, weight loss, itching, bloating. On examination, an enlarged, slightly painful liver is found. The course of the disease is usually not severe, but sometimes fatty hepatosis can turn into chronic hepatitis or cirrhosis of the liver.

    Diagnostics

    With ultrasound of the abdominal cavity - an increase in the echogenicity of the liver, an increase in its size. In a biochemical study of blood, a slight increase in the activity of liver tests and changes in protein fractions.

    Treatment

    First of all, one should either eliminate or minimize the effect of the factor that led to the deposition of fat in the liver. This is almost always possible in relation to alcohol, if it is not about the formation of dependence, when the help of a narcologist is required. Patients with diabetes mellitus and hyperlipidemia should be observed jointly by an endocrinologist and a cardiologist, respectively. All patients require a low-fat diet and sufficient daily physical activity.

    In obese patients, doctors usually consider it necessary to reduce the patient's body weight. The effect of weight loss on the course of fatty hepatosis is ambiguous. Rapid weight loss naturally leads to an increase in inflammation activity and progression of fibrosis. Reducing the weight nakg/year positively affects the severity of steatosis, inflammation and the degree of liver fibrosis. The most effective weight loss is considered to be no more than 1.6 kg / week, which is achieved with a daily caloric intake of 25 cal / kg / day.

    Fatty hepatosis of the liver in the ICD classification:

    Hello! Which doctor should I contact for treatment for a diagnosis of cirrhosis of the liver?

    Which doctors should I contact if fatty hepatosis of the liver occurs:

    Good afternoon. I am 67 years old, height 158 ​​cm, weight 78 kg. I started gaining weight after the death of my husband. I do not abuse alcohol. I walk moderately. What should I do? The analyzes are normal - and the ultrasound diagnosis: echo-signs of fatty hepatosis, chronic cholecystitis, chronic pancreatitis. What to do?

    Fatty hepatosis

    Liver problems have always been a big concern for many people. Indeed, if this important organ is out of order, then you can forget about the normal functioning of the whole organism. Yes, and the activity of the person himself turns out to be practically stopped until he begins the correct treatment of his illness.

    Many believe that liver problems are the result of a poor lifestyle or alcohol abuse. Often this is true, but there are still other reasons that affect the appearance of liver diseases. Diseases such as fatty liver can also occur due to completely different factors, which we will talk about.

    What is fatty liver disease?

    Under fatty hepatosis (another name is non-alcoholic steatohepatitis) is understood a certain process, as a result of which a fatty layer begins to form in the liver cells. Moreover, there is a picture when fat cells begin to completely replace healthy liver cells, which is a consequence of the accumulation of simple fats in healthy cells of the organ.

    According to the ICD-10, fatty liver disease has the code K 76 and the name "fatty liver degeneration".

    The liver performs the function of processing various toxins that are formed as a result of the use of alcoholic beverages and drugs. The body converts all these components into simple fats, but any person is already prone to eating fatty foods, so there is an excess of fat in the liver cells. It is at this moment that the accumulation of fat cells in the liver occurs, which leads to the appearance of the disease.

    Ignoring the treatment process, fat cells begin to accumulate, forming a full-fledged adipose tissue on the surface of the liver. Naturally, such a layer of fat prevents the body from performing its protective functions, leaving the body alone with various harmful toxins and similar substances.

    The danger of such a disease as fatty hepatosis lies in the possibility of developing into more serious diseases - fibrosis and cirrhosis of the liver, and this is an immediate threat to human life.

    To avoid this, it is necessary to diagnose the disease in a timely manner. At the first signs of the disease, you should contact the specialized specialists - an endocrinologist or a hepatologist. At the same time, the endocrinologist is responsible for treating the causes that led to the appearance of the disease, and the hepatologist treats the liver damage itself directly.

    The reasons

    For the correct preparation of the treatment regimen, it is necessary to find out which cause was the result of the occurrence of fatty hepatosis. Below are the most likely factors that directly affect the formation of fat cells, as well as their replacement of healthy ones:

    1. If a person is diagnosed with diseases in which fat metabolism is impaired. These include obesity, type 2 diabetes, and if a person has an elevated level of lipids in the blood.
    2. The effect of toxins on the body. The liver copes well with various kinds of toxins that enter the body along with certain foods and alcohol, but if this exposure is regular and intense, then the organ simply ceases to cope with the load. In particular, if a person regularly consumes alcohol, then he may develop alcoholic fatty hepatosis.
    3. If settlements are located near radioactive waste disposal sites, then there is a high risk of fatty liver among its inhabitants.
    4. Wrong food intake. If a person eats irregularly, there is not enough protein in his diet, then this disrupts the process of lipid metabolism. In addition, lovers of a beautiful figure who exhaust themselves with strict diets and starvation can also be included here. As a result of these actions, the body is depleted, which leads to the appearance of the disease.
    5. Improper functioning of the digestive system can also be a consequence of the appearance of fatty hepatosis.
    6. Antibiotics solve many problems, but they can also harm. Especially if the course of treatment is long, and at the end of it, restorative therapy in the form of taking probiotics was not carried out.
    7. Various endocrine diseases, which are expressed in a lack of thyroxine - a thyroid hormone, or excessive influence of cortisol, aldosterone and other hormones of the adrenal cortex.
    8. Of particular danger is fatty hepatosis during pregnancy, because there is a real risk to the fetus. At the same time, hepatosis is considered a disease of a hereditary nature, so it can be transmitted from mother to her child.

    Under the hour of pregnancy in the body of a woman, an increased formation of estrogens is observed, which leads to the occurrence of cholestasis. Hepatosis itself begins to develop against the background of active bile secretion into the blood. Experts note that fatty hepatosis occurs in those women who have previously suffered from any liver disease.

    Varieties of the disease

    The types of the disease differ in the degree of accumulation of fat cells. To date, there are several stages:

    On the organ there is a single or multiple accumulation of fat cells. Against their background, diffuse fatty hepatosis may develop.

  • Second degree

    With this form, the area of ​​​​fat accumulations increases, and connective tissue begins to form between the cells.

  • Third degree

    On the organ, connective tissue is already pronounced, which ends with fibroblasts. There is also a large accumulation of fat on the liver.

  • Symptoms

    Fatty hepatosis does not manifest itself immediately, so it is quite difficult to diagnose it at an early stage. It takes a certain amount of time before fat cells begin to take out healthy liver cells. Symptoms are most pronounced in the third degree, but it is better not to bring it up to this point, because in this case only a transplant of a healthy organ will help.

    Here is a list of the main symptoms:

    • vomit;
    • gagging;
    • blurred vision;
    • dysbacteriosis;
    • in the area of ​​​​the liver, a person begins to feel a feeling of heaviness;
    • dull skin tone.

    The insidiousness of this disease lies in the fact that these symptoms are not very pronounced, so a person quite often ignores them, believing that he just ate something wrong. Therefore, doctors advise not to be negligent to your health, but to contact specialists even with minor complaints and symptoms.

    Diagnostics

    If a patient goes to a specialist with the above symptoms, then the doctor should prescribe one of the following examinations:

    1. Ultrasound examination, which should show echoes of the disease.

    As a rule, ultrasound is enough for the timely diagnosis of fatty hepatosis. Even minor diffuse changes in the liver can be a cause for concern. To identify them, the following diagnostics are carried out:

    • Clinical and biochemical analysis of blood.
    • Echography.
    • Analysis of urine.
    • Ultrasound procedure.

    medical treatment

    The treatment of fatty liver is a combination of many actions, among many of which are taking medications, as well as a certain diet aimed at abandoning negative habits.

    Now Lopid, Troglitatazone and Actigall are used as medicines for this disease. In principle, all therapy should be based on the following factors:

    • Taking medications that normalize blood circulation.
    • Insulin medications.
    • Lipid balancing drugs.
    • Proper nutrition.

    In this video you will see clearly what happens to the liver during illness and how to cope with the disease.

    Treatment at home

    But in addition to traditional medicine, there is also folk medicine, which also turns out to be very effective in the treatment of fatty hepatosis. Many experts note that it is the treatment of folk remedies that allows you to get rid of this disease. The essence of this treatment is to take various decoctions that cleanse the liver.

    Here are some actionable recipes.

    If a person has an enlarged liver against the background of fatty hepatosis, then you can try the following recipe:

    • We take a few lemons, which we previously washed.
    • We grind them together with the peel in a blender, or pass through a meat grinder.
    • We take half a liter of boiling water and pour the resulting slurry of lemons, then leave it overnight.
    • The next day, it is necessary to strain the broth, and then take it during the day immediately before meals.
    • Remember that you can drink the infusion only three days in a row.

    In this video, even more recipes and methods of dealing with the disease.

    Diet

    Fatty hepatosis is a specific disease, which can be eliminated only if a person completely changes his lifestyle. We have already talked about giving up alcohol, but we will also have to normalize nutrition by following the right diet. Its basis is to minimize the amount of fat entering the body, so the steaming or boiling method should be used for cooking.

    • fatty meat broths;
    • meat and fish containing a large amount of fat;
    • garlic and onions;
    • legumes;
    • mushrooms;
    • tomatoes;
    • various kinds of canned products;
    • radish;
    • fatty sour cream and also cottage cheese;
    • smoked meats and pickles;
    • all carbonated drinks, coffee and cocoa should be deleted from the menu. You can replace them with green tea without sugar.

    As for allowed products, there are also several of them:

    • vegetables in any form, except stewed and fried;
    • milk soup;
    • soups and broths without meat;
    • low-fat cheese;
    • steamed omelet;
    • one boiled egg per day.
    • dairy products with low fat content;
    • various kinds of cereals from rice, oats, buckwheat, semolina, etc.;
    • you need to include any greens in the diet: parsley, dill, etc. They help to remove excess fats from the body, and they are very effective for preventive purposes;
    • you still need to eat the following foods: rice bran, apricot pits, watermelon, pumpkin, brewer's yeast, etc.
    • you should also include dried fruits in your daily diet: about 25 grams per day.

    Attention! You must understand that taking medications alone will not give the desired result. Only complex therapy based on a strict diet will help remove accumulated toxins and fats from the body.

    Watch this video for preventive measures.

    Fatty liver disease is not a disease that cannot be cured. If you do not run it to the extreme stage, when only a liver transplant can help, then you can get rid of this problem with the usual folk remedies and the right diet. Of course, you will have to give up the usual dishes and pleasures, but when the question of health arises, then other moments should be put on the back burner.

    Hundreds of suppliers bring hepatitis C medicines from India to Russia, but only M-PHARMA will help you buy sofosbuvir and daclatasvir, while professional consultants will answer any of your questions throughout the therapy.

    LIVER DISEASES (K70-K77)

    Included: medicinal:

    • idiosyncratic (unpredictable) liver disease
    • toxic (predictable) liver disease

    Use an additional external cause code (class XX) if necessary to identify the toxic substance.

    Excluded:

    • Budd-Chiari syndrome (I82.0)

    Included:

    • hepatic:
      • coma NOS
      • encephalopathy NOS
    • hepatitis:
      • fulminant, not elsewhere classified, with liver failure
      • malignant, not elsewhere classified, with liver failure
    • liver (cell) necrosis with liver failure
    • yellow atrophy or liver dystrophy

    Excluded:

    • alcoholic liver failure (K70.4)
    • liver failure complicating:
      • abortion, ectopic or molar pregnancy (O00-O07, O08.8)
    • fetal and neonatal jaundice (P55-P59)
    • viral hepatitis (B15-B19)
    • associated with toxic liver damage (K71.1)

    Excludes: hepatitis (chronic):

    • alcoholic (K70.1)
    • medicinal (K71.-)
    • granulomatous NEC (K75.3)
    • reactive nonspecific (K75.2)
    • viral (B15-B19)

    Excluded:

    • alcoholic fibrosis of the liver (K70.2)
    • cardial sclerosis of the liver (K76.1)
    • cirrhosis of the liver):
      • alcoholic (K70.3)
      • congenital (P78.3)
    • with toxic liver damage (K71.7)

    Excluded:

    • alcoholic liver disease (K70.-)
    • amyloid degeneration of the liver (E85.-)
    • cystic liver disease (congenital) (Q44.6)
    • hepatic vein thrombosis (I82.0)
    • hepatomegaly NOS (R16.0)
    • portal vein thrombosis (I81)
    • liver toxicity (K71.-)

    In Russia, the International Classification of Diseases of the 10th revision (ICD-10) is adopted as a single regulatory document for accounting for morbidity, reasons for the population to apply to medical institutions of all departments, and causes of death.

    ICD-10 was introduced into healthcare practice throughout the Russian Federation in 1999 by order of the Russian Ministry of Health dated May 27, 1997. №170

    The publication of a new revision (ICD-11) is planned by WHO in 2017 2018.

    With amendments and additions by WHO.

    Processing and translation of changes © mkb-10.com

    Source: http://mkb-10.com/index.php?pid=10331

    K70-K77 Diseases of the liver. V. 2016

    International Classification of Diseases 10th Revision (ICD-10)

    K70-K77 Diseases of the liver

    K70-K77 Diseases of the liver

    Reye's syndrome (G93.7)

    viral hepatitis (B15-B19)

    K70 Alcoholic liver disease

    K71 Liver toxicity

    Budd-Chiari syndrome (I82.0)

    "Pure" cholestasis K71.1 Toxic liver damage with hepatic necrosis Hepatic failure (acute) (chronic), due to drugs K71.2 Toxic liver damage, proceeding according to the type of acute hepatitis

    yellow atrophy or dystrophy of the liver

    liver failure complicating:

    • abortion, ectopic or molar pregnancy (O00-O07, O08.8)
    • pregnancy, childbirth and the puerperium (O26.6)

    fetal and neonatal jaundice (P55-P59)

    viral hepatitis (B15-B19)

    associated with toxic liver injury (K71.1)

    K74 Fibrosis and cirrhosis of the liver

    cardial sclerosis of the liver (K76.1)

    cirrhosis of the liver:

    • alcoholic (K70.3)
    • congenital (P78.3)

    with toxic liver damage (K71.7-) K74.0 Liver fibrosis

    • acute or subacute
      • NOS (B17.9)
      • not viral (K72.0)
    • viral hepatitis (B15-B19)

    liver toxicity (K71.1)

    cholangitis without liver abscess (K83.0)

    pylephlebitis without liver abscess (K75.1) K75.1 Phlebitis of the portal vein Pylephlebitis Ruled out: pylephlebitic liver abscess (K75.0)

    amyloid degeneration of the liver (E85.-)

    cystic liver disease (congenital) (Q44.6)

    hepatic vein thrombosis (I82.0)

    portal vein thrombosis (I81.-)

    liver toxicity (K71.-)

    Focal nodular hyperplasia of the liver

    Hepatoptosis K76.9 Liver disease, unspecified

    Portal hypertension in schistosomiasis B65.- †)

    Liver damage in syphilis (A52.7 †) K77.8* Liver damage in other diseases classified elsewhere Hepatic granulomas in:

    • berylliose (J63.2†)
    • sarcoidosis (D86.8 †)

    Notes. 1. This version corresponds to the 2016 version of the WHO (ICD-10 Version: 2016), some positions of which may differ from the version of the ICD-10 approved by the Ministry of Health of Russia.

    2. Translation into Russian of a series medical terms in this article may differ from the translation in the ICD-10 approved by the Ministry of Health of Russia. All comments and clarifications on translation, design, etc. are accepted with gratitude by e-mail.

    3. NOS - without additional specifications.

    4. NEC - not elsewhere classified.

    5. A cross † marks the main codes of the underlying disease, which must be used without fail.

    6. An asterisk marks optional additional codes related to the manifestation of the disease in a separate organ or area of ​​the body, which is an independent clinical problem.

    Source: http://www.gastroscan.ru/handbook/382/7735

    What is fatty liver: ICD code 10

    The development of fatty hepatosis is based on the violation of metabolic processes in the human body. As a result of this liver disease, healthy tissue of the organ is replaced by fatty tissue. At the initial stage of development, fat accumulates in hepatocytes, which over time simply leads to dystrophy of the liver cells.

    If the disease is not diagnosed at an early stage and appropriate therapy is not carried out, then irreversible inflammatory changes occur in the parenchyma, which lead to the development of tissue necrosis. If fatty liver is not treated, it can develop into cirrhosis, which is no longer treatable. In the article, we will consider the reason for the development of the disease, methods of its treatment and classification according to ICD-10.

    Causes of fatty liver and its prevalence

    The causes of the development of the disease have not yet been exactly proven, but factors are known that can surely provoke the onset of this disease. These include:

    • completeness;
    • diabetes;
    • violation of metabolic processes (lipid);
    • minimal physical activity with a nutritious daily diet high in fat.

    Most cases of development of fatty hepatosis are recorded by physicians in developed countries with above-average living standards.

    There are a number of other factors associated with hormonal disruptions, such as insulin resistance and the presence of sugar in the blood. You can not omit the hereditary factor, it also plays a big role. But still, the main reason is malnutrition, a sedentary lifestyle and excess weight. All causes are in no way related to the intake of alcoholic beverages, so fatty hepatosis is often called non-alcoholic. But if alcohol addiction is added to the above reasons, then fatty hepatosis will develop many times faster.

    In medicine, it is very convenient to use the coding of diseases to systematize them. It is even easier to indicate a diagnosis on a sick leave using a code. Codes for all diseases are presented in the International Classification of Diseases, Injuries and Various Health Problems. The tenth revision is currently in effect.

    All liver diseases according to the International Classification of the Tenth Revision are encrypted under the codes K70-K77. And if we talk about fatty hepatosis, then according to ICD 10, it falls under the code K76.0 (fatty degeneration of the liver).

    You can learn more about the symptoms, diagnosis and treatment of hepatosis from separate materials:

    Treatment of fatty liver

    The treatment regimen for non-alcoholic hepatosis is to eliminate possible risk factors. If the patient is obese, then you need to try to optimize it. And start by reducing the total mass by at least 10%. Doctors recommend using minimal physical activity in parallel with dietary nutrition to achieve the goal. Limit the use of fats in the diet as much as possible. At the same time, it is worth remembering that a sharp weight loss will not only not be beneficial, it can, on the contrary, damage, aggravating the course of the disease.

    For this purpose, the attending physician may prescribe thiazolidinoids in combination with biguanides, but this line of drugs has not yet been fully studied, for example, for hepatotoxicity. Metformin can help correct the process of metabolic disorders in carbohydrate metabolism.

    As a result, we can confidently say that with the normalization of the daily diet, a decrease in body fat and giving up bad habits, the patient will feel better. And only in this way it is possible to fight such a disease as non-alcoholic hepatosis.

    Source: http://zapechen.ru/bolezni-pecheni/gepatoz/mkb-10.html

    Steatosis of the liver

    ICD-10 code

    Related diseases

    Titles

    Description

    Symptoms

    The reasons

    Metabolic disorders - type 2 diabetes mellitus, obesity, hypertriglyceridemia;

    The action of toxic factors - alcohol, certain toxic substances, drugs;

    Unbalanced diet (overeating, starvation, lack of protein in food);

    Chronic diseases of the digestive system with malabsorption syndrome and;

    Fatty infiltration of the liver that is not associated with the effects of alcohol or other toxic substances is called primary or non-alcoholic steatosis (non-alcoholic fatty liver disease). Thus, liver damage is not always associated with the action of toxic factors (alcohol, drugs).

    Today, the prevalence of non-alcoholic fatty liver disease is very significant. Approximately a quarter of the population in developed countries has steatosis of the liver, and 3.5-11% have non-alcoholic steatohepatitis, including cirrhosis of the liver. Obese people are diagnosed with non-alcoholic fatty liver disease much more often than people with normal weight.

    Risk factors for severe disease:

    Source: http://kiberis.ru/?p=30417

    Fatty liver (K76.0)

    Version: Directory of Diseases MedElement

    general information

    Short description

    Fatty degeneration of the liver is a disease characterized by liver damage with changes similar to changes in alcoholic liver disease (fatty degeneration of hepatocytes hepatocyte is the main liver cell: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, neutralization of toxic substances and the formation of bile (Hepatocyte)

    ), however, with fatty degeneration of the liver, patients do not drink alcohol in quantities that can cause liver damage.

    Definitions most commonly used in NAFLD:

    1. Non-alcoholic fatty liver disease (NAFL). The presence of fatty degeneration of the liver without signs of damage to hepatocytes hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

    in the form of balloon dystrophy or without signs of fibrosis. The risk of developing cirrhosis and liver failure is minimal.

    2. Non-alcoholic steatohepatitis (NASH). The presence of liver steatosis and inflammation with damage to hepatocytes hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

    (balloon dystrophy) with or without signs of fibrosis. May progress to cirrhosis, liver failure, and (rarely) liver cancer.

    3. Non-alcoholic cirrhosis of the liver (NASH Cirrhosis). Presence of evidence of cirrhosis with current or previous histological evidence of steatosis or steatohepatitis.

    4. Cryptogenic cirrhosis (Cryptogenic Cirrhosis) - cirrhosis without obvious etiological causes. Patients with cryptogenic cirrhosis usually have high risk factors associated with metabolic disorders such as obesity and metabolic syndrome. Increasingly, cryptogenic cirrhosis, when examined in detail, turns out to be an alcohol-associated disease.

    5. Assessment of NAFLD activity (NAS). The totality of points calculated in the complex assessment of the signs of steatosis, inflammation and balloon degeneration. It is a useful tool for the semi-quantitative measurement of histological changes in liver tissue in patients with NAFLD in clinical trials.

    K75.81 - Non-alcoholic steatohepatitis (NASH)

    K74.0 - Fibrosis of the liver

    K74.6 - Other and unspecified cirrhosis of the liver.

    Classification

    Types of fatty liver degeneration:

    1. Macrovesicular type. The accumulation of fat in hepatocytes is local in nature and the nucleus of the hepatocyte shifts away from the center. With fatty infiltration of the liver of the macrovesicular (large-drop) type, triglycerides, as a rule, act as accumulated lipids. At the same time, the morphological criterion of fatty hepatosis is the content of triglycerides in the liver over 10% of the dry mass.

    2. Microvesicular type. The accumulation of fat occurs evenly and the core remains in place. In microvesicular (fine) fatty degeneration, other (non-triglycerides) lipids (eg, free fatty acids) accumulate.

    There are also focal and diffuse hepatic steatosis. The most common diffuse steatosis, which is zonal in nature (the second and third zone of the lobule).

    Etiology and pathogenesis

    Primary non-alcoholic fatty disease is considered as one of the manifestations of the metabolic syndrome.

    Hyperinsulinism leads to activation of the synthesis of free fatty acids and triglycerides, a decrease in the rate of beta-oxidation of fatty acids in the liver and the secretion of lipids into the bloodstream. As a result, fatty degeneration of hepatocytes develops hepatocyte - the main cell of the liver: a large cell that performs various metabolic functions, including the synthesis and accumulation of various substances necessary for the body, the neutralization of toxic substances and the formation of bile (Hepatocyte)

    The occurrence of inflammatory processes is predominantly centrilobular in nature and is associated with increased lipid peroxidation.

    Of particular importance is the increased absorption of toxins from the intestines.

    A sharp decrease in body weight;

    Chronic protein-energy deficiency.

    Inflammatory bowel disease;

    Celiac Disease Celiac disease is a chronic disease caused by a lack of enzymes involved in the digestion of gluten.

    Diverticulosis of the small intestine;

    Microbial contamination Contamination is the entry into a certain environment of any impurity that changes the properties of this environment.

    Operations on the gastrointestinal tract.

    Diabetes mellitus type II;

    triglyceridemia, etc.

    Epidemiology

    Prevalence sign: Common

    Sex ratio (m/f): 0.8

    The prevalence is estimated to be between 1% and 25% of the general population in various countries. In developed countries, the average level is 2-9%. Many findings are incidentally discovered during liver biopsy performed for other indications.

    Most often, the disease is detected at age, although no age (except for breastfed children) excludes the diagnosis.

    The sex ratio is unknown, but a female predominance is assumed.

    Factors and risk groups

    The high risk group includes:

    more than 30% of cases is associated with the development of hepatic steatosis Hepatic steatosis is the most common hepatosis, in which fat accumulates in the liver cells

    and in 20-47% with non-alcoholic steatohepatosis.

    2. Persons with type 2 diabetes mellitus or impaired glucose tolerance. In 60% of patients, these conditions occur in combination with fatty degeneration, in 15% - with non-alcoholic steatohepatitis. The severity of liver damage is related to the severity of impaired glucose metabolism.

    3. Persons diagnosed with hyperlipidemia, which is detected in 20-80% of patients with non-alcoholic steatohepatitis. A characteristic fact is the more frequent combination of non-alcoholic steatohepatitis with hypertriglyceridemia than with hypercholesterolemia.

    4. Women of middle age.

    and uncontrolled blood pressure. There is a higher prevalence of fatty liver in hypertensive patients without risk factors for developing fatty liver. The prevalence of the disease is estimated to be almost 3 times higher than in control groups matched by age and sex and keeping blood pressure at the recommended level.

    Malabsorption syndrome Malabsorption syndrome (malabsorption) - a combination of hypovitaminosis, anemia and hypoproteinemia, caused by malabsorption in the small intestine

    (as a consequence of the imposition of the ileojejunal Ileojejunal - relating to the ileum and jejunum.

    anastomosis, extended resection of the small intestine, gastroplasty for obesity, etc.);

    and some others.

    Clinical picture

    Clinical Criteria for Diagnosis

    Symptoms, course

    Most patients with non-alcoholic fatty liver disease have no complaints.

    Minor discomfort in the upper right quadrant of the abdomen (about 50%);

    Pain in the upper right quadrant of the abdomen (30%);

    Moderate hepatosplenomegaly Hepatosplenomegaly - simultaneous significant enlargement of the liver and spleen

    Arterial hypertension AG (arterial hypertension, hypertension) - persistent increase in blood pressure from 140/90 mm Hg. and higher.

    Dyslipidemia Dyslipidemia is a metabolic disorder of cholesterol and other lipids (fats), which consists in a change in their ratio in the blood

    Impaired glucose tolerance.

    The appearance of telangiectasia Telangiectasia is a local excessive expansion of capillaries and small vessels.

    Palmar erythema Erythema - limited hyperemia (increased blood supply) of the skin

    Ascites Ascites - accumulation of transudate in the abdominal cavity

    Jaundice, gynecomastia Gynecomastia - an increase in the mammary glands in men

    Signs of liver failure and other signs of fibrosis, cirrhosis, non-infectious hepatitis require coding in the appropriate subheadings.

    Identified association with alcohol, medication, pregnancy and other etiological causes also requires coding in other subcategories.

    Diagnostics

    Laboratory diagnostics

    are detected in 50-90% of patients, but the absence of these signs does not exclude the presence of non-alcoholic steatohepatitis (NASH).

    The level of serum transaminases increased slightly - 2-4 times.

    The value of the AST/ALT ratio in NASH:

    Less than 1 - observed in the initial stages of the disease (for comparison, in acute alcoholic hepatitis, this ratio is usually > 2);

    Equal to 1 or more - may be an indicator of more pronounced liver fibrosis;

    More than 2 - is considered as an unfavorable prognostic sign.

    2. In 30-60% of patients, an increase in the activity of alkaline phosphatase (usually no more than twofold) and gamma-glutamyl transpeptidase (may be isolated, not associated with an increase in alkaline phosphatase) is detected. A GGTP level > 96.5 U/L increases the risk of fibrosis.

    3. In 12-17% of cases, hyperbilirubinemia occurs within% of the norm.

    In clinical practice, insulin resistance is measured by the ratio of immunoreactive insulin and blood glucose levels. It should be remembered that this is a calculated indicator, which is calculated by various methods. The indicator is influenced by the level of triglycerides in the blood and race.

    7. Hypertriglyceridemia occurs in 20-80% of patients with NASH.

    Many patients will have low HDL as part of the metabolic syndrome.

    As the disease progresses, cholesterol levels often decrease.

    It should be kept in mind that a low positive antinuclear antibody titer is not uncommon in NASH, and less than 5% of patients may have a positive low titer of antibodies to smooth muscle.

    more characteristic of cirrhosis or severe fibrosis.

    Unfortunately, this indicator is not specific; in case of its increase, it is necessary to exclude a number of oncological diseases (bladder, breast, etc.).

    11. Comprehensive biochemical tests (BioPredictive, France):

    Steato-test - allows you to identify the presence and degree of liver steatosis;

    Nash test - allows you to identify NASH in patients with overweight, insulin resistance, hyperlipidemia, as well as patients with diabetes mellitus).

    It is possible to use other tests for suspected non-alcoholic fibrosis or hepatitis - Fibro-test and Akti-test.

    Differential Diagnosis

    Complications

    Fibrosis Fibrosis is an overgrowth of fibrous connective tissue that occurs, for example, as a result of inflammation.

    Cirrhosis of the liver Cirrhosis of the liver is a chronic progressive disease characterized by dystrophy and necrosis of the hepatic parenchyma, accompanied by its nodular regeneration, diffuse proliferation of connective tissue and a deep restructuring of the liver architectonics.

    In detail (develops especially rapidly in patients with tyrosinemia Tyrosinemia is an increased concentration of tyrosine in the blood. The disease leads to increased urinary excretion of tyrosine compounds, hepatosplenomegaly, nodular cirrhosis of the liver, multiple defects in renal tubular reabsorption and vitamin D resistant rickets. Tyrosinemia and tyrosyl excretion occur when a number of inherited (p) fermentopathies: fumarylacetoacetase deficiencies (type I), tyrosine aminotransferase (type II), 4-hydroxyphenylpyruvate hydroxylase (type III)

    Almost bypassing the stage of "pure" fibrosis);

    Liver failure (rarely - in parallel with the rapid formation of cirrhosis).

    Treatment

    Forecast

    Life expectancy in non-alcoholic fatty liver disease is not lower than in healthy individuals.

    Half of the patients develop progressive fibrosis, and 1/6 - cirrhosis of the liver.

    Hospitalization

    Prevention

    1. Normalization of body weight.

    2. Patients should be screened for hepatitis viruses. In the absence of viral hepatitis, they should be offered vaccination against hepatitis B and A.

    Source: http://diseases.medelement.com/disease/%D0%B6%D0%B8%D1%80%D0%BE%D0%B2%D0%B0%D1%8F-%D0%B4%D0% B5%D0%B3%D0%B5%D0%BD%D0%B5%D1%80%D0%B0%D1%86%D0%B8%D1%8F-%D0%BF%D0%B5%D1%87 %D0%B5%D0%BD%D0%B8-k76-0/4827

    Non-alcoholic steatohepatitis: from pathogenesis to therapy

    Danilevskaya N.N. – gastroenterologist GKB 50, Moscow

    Non-alcoholic steatohepatitis (NASH) is a inflammatory infiltration parenchyma and stroma of the liver with the presence of focal necrosis. NASH is an intermediate link among the successive stages of one pathological process (non-alcoholic steatosis and non-alcoholic steatofibrosis) and is included in an independent metabolic disease - non-alcoholic fatty liver disease (NAFLD). Since the ICD-10 list of diseases does not contain a single code that reflects the completeness of the diagnosis of NAFLD, currently the most commonly used: K 76.0 - fatty degeneration of the liver, not classified in other headings.

    The term NASH was first formulated in 1980 by J. Ludwig et al., studying the nature of changes in the liver of patients with obesity and type 2 diabetes mellitus, who had no history of alcohol intake in hepatotoxic doses, however, during a morphological study of liver tissue, there were revealed signs characteristic of alcoholic liver disease. And the term non-alcoholic fatty liver disease (non-alcoholic fatty liver disease), introduced in 2000, is now used as a general name for various dysmetabolic conditions of the liver, which are based on excessive intra- and extracellular fat accumulation. At the same time, it is necessary to exclude chronic alcohol intoxication (when the consumption of alcohol-containing products in terms of pure ethanol is less than 20 g / day), hereditary hemochromatosis, HCV, HBV and HDV infections, increased levels of ceruloplasmin and α1-antitrypsin, make sure that there is no autoimmune hepatitis.

    It must be remembered that there is a certain number of patients who do not drink alcohol, but have liver damage that is similar in histological structure to alcohol.

    Studies conducted in Japan and Italy have shown that the prevalence of fatty liver in the general population ranges from 3 to 58% (median 23%). The high variability in these data is probably due to the socio-economic differences of the studied settlements.

    In the US, non-alcoholic steatohepatitis is the most common illness. The percentage of obese people in the general population increased from 10% to 25% from 1961 to 1997 alone. In European countries, NASH is diagnosed in approximately 11% of patients undergoing liver biopsy due to elevated serum transaminases. In obese people, the prevalence of NASH is higher, at 19%, and only 2.7% of cases of NASH are diagnosed at normal weight.

    In fact, the prevalence of NASH may be even higher among asymptomatic patients who do not consume significant amounts of alcohol, if there are no serological markers of viral hepatitis. Thus, many patients with elevated liver enzymes in the blood and negative results of non-invasive tests may have NASH. There are reports of cases of NASH detected at the age of years.

    NASH pathogenesis is based on peripheral insulin resistance. Through tyrosine kinase, intracellular disruption of signaling occurs after activation of the insulin receptor. The exact mechanism of disruption of this metabolic pathway is not completely clear. Apparently, the release of TNF-α, as well as leptin and a number of other protein mediators, by adipose tissue, especially the adipose tissue of the mesentery, becomes decisive. TNF-α downregulates the insulin receptor-substrate signal and thereby reduces translocation of the glucose-transporting protein GLUT-4 on the cell membrane. As a result, the amount of glucose utilized by the cell decreases. Peripheral insulin resistance leads to hyperinsulinism, which blocks mitochondrial β-oxidation. The adipose tissue hormone leptin also has essential. Leptin resistance or deficiency leads to increased fat accumulation and impaired fatty acid β-oxidation in the liver. Also, in NAFLD, the level of the adipose tissue hormone adiponectin decreases, and therefore, intracellular signals, such as the activation of MAP kinase and peroxisomal proliferative nuclear receptor, are disturbed, which increases the accumulation of fat in the liver. Free fatty acids have a hepatotoxic effect. Normally, FFAs are neutralized in the following ways: mitochondrial β-oxidation, VLDL production and secretion, fatty acid-binding protein synthesis, and triglyceride synthesis.

    In NAFLD, the various mechanisms for neutralizing free fatty acids are limited. Fatty liver, due to the second pathophysiological mechanism, can become the basis for the progression of liver pathology to NASH with fibrosis. In this regard, it is important that free fatty acids can induce cytochrome PE1 with subsequent production of reactive oxygen species, which, by enhancing lipid peroxidation, lead to the activation of fibroneogenesis. Another mechanism is represented by an increased supply of endotoxins from the intestine to the liver. As with alcoholic liver disease, cytokines are secreted by Kupffer's stellate cells. Cytokines, primarily TNF-α, contribute, on the one hand, to the pathogenesis of hepatitis, and on the other hand, to the development of peripheral insulin resistance. Among the causes leading to NASH, congenital and acquired metabolic disorders are considered: Wilson-Konovalov disease, metabolic syndrome, total parenteral nutrition, severe weight loss, as well as rare pathologies - abetalipoproteinemia, hypobetaliproproteinemia, tyrosinemia, peroxisome pathology, mitochondriopathy. Polycystic ovaries, celiac disease, contact with solvents matter. Surgical interventions such as gastric banding, extensive small bowel resection, biliopancreatic anastomosis, or ileo-intestinal anastomosis are also known to contribute to the development of NASH. A number of drugs from various pharmacological groups(chloroquine, diltiazem, nifedipine, amiodarone, glucocorticoids, tamoxifen, estrogens, isoniazid, methotrexate, nucleoside analogues) cause NASH.

    Clinic and diagnosis of NASH

    The relevance of timely diagnosis and treatment of NASH is associated, on the one hand, with the fact that NAFLD, along with obesity, type 2 diabetes mellitus, arterial hypertension, and dyslipidemia, is a component of the metabolic syndrome and is an independent risk factor for cardiovascular diseases. At the same time, according to the accumulated data, NASH accounts for 20% of all cases of NAFLD. On the other hand, it was previously believed that NASH proceeds benignly and rarely progresses to decompensated liver cirrhosis, but it has now been shown that cirrhosis can develop in 40% of cases of NASH and the progression of NASH to cirrhosis is determined by the severity of inflammatory changes in hepatocytes. In addition, the disease affects all age groups, including children.

    True data on the prevalence of NASH are scarce, due to its low and asymptomatic course. Patients rarely complain or they are not specific even at an advanced stage of the disease. Often the possibility of developing NASH is discussed when an increase in transaminase levels is detected, hepatomegaly is detected during examination or according to imaging methods. An increase in liver echogenicity on ultrasound was found in 14% of 2574 randomly selected residents of Japan. Since ultrasound only detects fat deposition and not inflammation, not all of these cases can be considered NASH. Also, with overweight, there may be a discrepancy in the conclusions of ultrasound performed by different specialists, due to an increase in the thickness of the subcutaneous fat layer, which entails technical difficulties in performing the study and makes it difficult to assess the echogenicity of the liver. The definitive diagnosis of NASH is based on the results of a liver biopsy. According to autopsy data, NASH occurs in 18.5% of cases of obesity and in 2.7% of healthy individuals. In the US, 20% of clinically healthy liver donors have fatty infiltration, and 7.5% have NASH. In Japan, fatty infiltration was found in 9.2% of liver donors. Histologically, fatty degeneration of the liver manifests itself in the form of macrovesicular fatty deposits in hepatocytes and infiltration of the liver tissue with neutrophils and mononuclear cells; in some advanced cases, signs of fibrosis or cirrhosis may be present.

    Among the laboratory parameters that most often change with NASH, the most common is a 2-3-fold increase in the activity of ALT and AST. In relation to AST/ALT, NASH can be differentiated in most cases (Treatment

    Treatment of NASH is empiric, and there are no generally accepted methods. General recommendations compliance with a hypocaloric diet, the fight against hypodynamia are recognized. Laboratory and histological abnormalities, as well as the size of the liver, with a gradual decrease in body weight, may decrease. However, improvement is possible even in the presence of persistent obesity. It has also been observed that rapid weight loss is accompanied by NASH progression. In addition, the long-term positive impact of weight loss is difficult to assess, since this requires maintaining a reduced body weight, and patients with NASH and obesity rarely succeed. Liver transplantation is effective in decompensated cirrhosis within NASH, but NASH in the graft can recur, especially against the background of weight gain and dyslipidemia. Follow-up data after liver transplantation for NASH are scarce, but its recurrence has been described as early as 6–10 weeks.

    For drug therapy drugs of various pharmacological groups are used. Given the role of insulin resistance in the pathogenesis of NASH, the use of biguanides and thiazolidinediones is relevant, the effects of which are due to a decrease in gluconeogenesis and lipid synthesis in the liver, an increase in insulin sensitivity, thereby contributing to a decrease in obesity.

    Preparations containing essential phospholipids are used, which are elements in the structure of the membrane of the liver cell organelles and have a normalizing effect on the metabolism of lipids and proteins. . In small and short-term studies, it has been shown that taking α-tocopherol (vitamin E); combinations of lecithin, vitamin C and low doses of vitamin E; β-carotene; Selena; B vitamins slightly improves liver function.

    Recently, the greatest therapeutic efficacy in NASH has been found in ursodeoxycholic acid (UDCA) preparations. In pilot studies, the use of UDCA (in dozemg/kg/day) for 12 months was accompanied by a significant improvement in liver tests, lipid metabolism, a decrease in liver steatosis, without a significant decrease in body weight.

    UDCA is a stereoisomer of deoxycholic bile acid, formed under the action of the microflora of the large intestine. Numerous experimental and clinical researches make it possible to distinguish the diverse properties and effects of UDCA. The hepatoprotective effect develops due to the fact that UDCA is able to integrate into the phospholipid layer of the cell membrane, which contributes to its stability and increased resistance to damaging factors. The anticholestatic effect is determined by the induction of bicarbonate choleresis, which enhances the excretion of hydrophobic bile acids into the intestine; anti-apoptotic effect - due to the displacement of a pool of toxic hydrophobic bile acids that have a toxic effect on hepatocytes and cholangocytes. The immunomodulatory properties of UDCA (due to a decrease in the expression of HLA class I molecules on hepatocytes and HLA class II molecules on cholangiocytes and a decrease in the production of pro-inflammatory cytokines), litholytic (due to slower cholesterol crystallization) and hypocholesterolemic (reduces absorption of cholesterol in the intestine, its synthesis in the liver and excretion) are also described. into bile) effects. The positive effect of UDCA on the biochemical parameters of cytolysis and cholestasis in NASH has been described in many studies, and the diverse effects of UDCA determine the use of the drug in a wide range of liver diseases.

    Currently, a new drug Choludexan (World Medicine, Great Britain) has appeared on the Russian market, each capsule of which contains 300 mg of UDCA. The growing interest in UDCA preparations, in particular Choludexan, is not accidental, since its pharmacotherapeutic effect is diverse and, of course, is not limited to non-alcoholic steatohepatitis. Indications for the appointment of Choludexan, in addition to NASH, are: uncomplicated cholelithiasis(biliary sludge; dissolution of cholesterol gallstones in gallbladder if it is impossible to remove them by surgical or endoscopic methods; prevention of recurrence of stone formation after cholecystectomy); chronic active hepatitis; toxic (including medicinal) liver damage; alcoholic liver disease (ALD); primary biliary cirrhosis of the liver; primary sclerosing cholangitis; cystic fibrosis; atresia of the intrahepatic biliary tract, congenital atresia of the bile duct; biliary dyskinesia with proven efficacy of UDCA in all these diseases.

    It should be noted that, unlike other drugs, Choludexan has a more convenient dosage - 300 mg. As L. Vasiliev, 2008, wrote in his article: “Let's face it: in the production of any medicine, you should rely not on a conscientious, but on a lazy patient, and the fewer capsules he needs to take per day, the more chances that he complete the course of treatment. . It can be added that the advantage of a dosage of 300 mg lies in the convenience of calculating the dose of the drug per kg of the patient's weight, depending on the diagnosis (for NASH, Choludexan is used at the rate of mg / kg / day from 6 months to several years).

    Of particular value are the properties of Choludexan in comorbid vascular patients, the number of which is growing from year to year. Thus, the effectiveness of UDCA in NASH in patients with coronary artery disease has been noted in several studies. In a study conducted in 2006 in Ukraine, the functional state of the liver of patients with coronary artery disease in combination with NSAH, who received lipid-lowering therapy with statins and UDCA (Choludexan 300 mg) for three months, was studied. There was a decrease in total cholesterol by 23–24%, triglycerides by 40–41%, LDL by 35–36%, very low density lipoproteins by 25%, atherogenic index by 13–14%, an increase in HDL by 42%. A significant decrease in ALT activity (by 56%) was observed in patients treated with statins and UDCA. The results of the study of the effectiveness of UDCA (Choludexan 300 mg) and statins in NASH and IHD indicate the validity of the use of drugs in order to achieve a hypolipidemic and cytoprotective effect, as well as the absence of adverse reactions when combined.

    In addition, despite the relatively benign course of NASH, in half of the cases progression of the pathological process and occasionally the formation of liver cirrhosis are noted, the appointment of UDCA in patients with coronary artery disease and hyperlipidemia is justified. So, UDCA (Choludexan 300 mg) in combination with statins probably has a potentiating hypolipidemic effect, leading to the normalization of the lipid spectrum in patients with coronary artery disease and NSAH. At the same time, against the background of a combination of drugs, there is no deterioration in the metabolic function of the liver, which causes the abolition of statin treatment.

    In general, Choludexan is given orally once a day at bedtime or twice a day. The capsule is swallowed whole, without chewing, with a sufficient amount of liquid. In the treatment of chronic liver diseases, the dosage of Choludexan is mg / kg of body weight per day, the duration of treatment is from several months to 2 years.

    1. Ludwig J., Viggiano T.R. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin Proc. 1980, 55:434-8.

    2. L.I. Butorova “Non-alcoholic fatty liver disease as a manifestation of the metabolic syndrome: epidemiology, pathogenesis, clinical features

    manifestations, principles of diagnosis, modern possibilities of treatment”. Moscow 2012.

    3. M. Carneiro de Mur. Non-alcoholic steatohepatitis // Clinical perspectives in gastroenterology, hepatology. - 2001. - No. 2. - S. 12-15.

    4. Fadeenko G.D. Fatty liver: etiopathogenesis, diagnosis, treatment // Modern gastroenterology .. - 2003. - No. 3 (13). - P. 9-17.

    5. Severov M. Non-alcoholic fatty liver disease // Vrach.- 2002. - No. 10.- P.23-26. ,1212.

    6. Bellentani S, Tinbelli C. Epidemiology and risk factors for fatty liver. In: Leuschner U. James OFW, Dancygier H (eds.). Steatohepatitis (NASH and ASH), Kluwer Academic Publishers, Dordrecht 2001, 3-10.].

    7. M. Carneiro de Mur. Non-alcoholic steatohepatitis // Clinical perspectives in gastroenterology, hepatology. - 2001. - No. 2. - S. 12-15].

    8. Sherlock Sh, Dooley J. Diseases of the liver and biliary tract (translated from English), Moscow, 1999, p..

    9. Yakovenko E.P., Grigoriev P.Ya., Agafonov N.A., Yakovenko A.V. Metabolic diseases of the liver: problems of therapy // Farmateka. - 2003. - No. 10. - S. 47-52.

    10. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132:.

    11. Chitturi S., Abeygunaskera S., Farrell G.C et al. NASH and insulin resistance: insulin hepersecretion and specific association with the insulin resistance Syndrom // Hepatology/– N 35. – P..

    12. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single topic Conference// Hepatology/– N 37. – P..

    13. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnor-malities// Gastroenterology/. - N20. -P..].

    14. Oneta C.M., Dufour J.F. Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations //Swiss Med.Wkly. - 2002. - N132. – P..

    15. A.O. Bueverov Hepatitis. Rational diagnostics. Geotar-Media.. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis //N.Engl. J. Med. – 2000. – N 343. – P..

    17. Peter R. McNally Secrets of Gastroenterology Second Edition. Binom 2005

    18. M. Carneiro de Mur. Non-alcoholic steatohepatitis // Clinical perspectives in gastroenterology, hepatology. - 2001. - No. 2. - S. 12-15.

    19. Ch. Pavlov, I. Bakulin Non-alcoholic steatohepatitis: clinical features and principles of treatment // Doctor, 2007, No. 10, p. 24-28

    20. Yu.M. Stepanov, A.Yu. Filippova, Liver steatosis and non-alcoholic steatohepatitis: a modern view on the pathogenesis, diagnosis and treatment// Health of Ukraine.2004

    21 Ceriani R, Brunati S, Morini L et al. Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis (Abstract). Hepatology 1998; 28:386A (No. 894)

    22 Guma C, Viola L, Thome M et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial (Abstract). Hepatology 1997; 26:387A (No. 1036).

    23. I.G. Bakulin, Yu.G. Sandler Possibilities of using hepatoprotectors in the practice of a general practitioner Consilium Medicum volume 12 / №8 2010,

    24. Rational pharmacotherapy of diseases of the digestive system / under the general editorship of V.T. Ivashkin. M.: Litterra, 2007.,

    25. Bueverov A.O. Possibilities of clinical application of ursodeoxycholic acid. Cons. Med. 2005; 7(6).

    26. Holoman J., Glasa J., Kasar J. et al. Serum markers of liver fibrosis in patients with non-alcocholic steatohepatitis (NASH). Correlation to morphology and effect of therapy. J Hepatol 2000;32:210.

    27. Nadinskaya M.Yu. A study of the use of ursodeoxycholic acid in hepatology from the perspective of evidence-based medicine. Consilium medicum 2003;6:

    28. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001;35:134–46.

    29. Fedorov I.G., Baikova I.E., Nikitin I.G., Storozhakov G.I. Non-alcoholic steatohepatitis: clinic, pathogenesis, diagnosis, treatment. Rosmed 2004;2:46–49.

    30. Dolzhenko M.N. Patient with ischemic disease heart and chronic steatohepatitis: how to carry out hypolidemic correction? Ukrmed zh 2007;1(57).

    31. Shipulin V.P., Dolzhenko M.N. Chronic steatohepatosis: a prospective study of functional status of cardio-vascular system. Krym Med Zh 2006; 3:12–16.

    32. Rational pharmacotherapy of diseases of the digestive system. Ed. V.T.Ivashkina, T.L.Lapina. M.: Literra, 2006; 552 p.

    33. Vasiliev L, Healthy as ... a bear. Magazine "Pharmacist", No. 1, 2008.

    Masharova A.A. - Doctor of Medical Sciences, Professor of the Department of Therapy, Clinical Pharmacology and SMP MGMSU (Moscow), Chief Gastroenterologist of the SAO DZ of Moscow

    Danilevskaya N.N. – gastroenterologist of the gastroenterological department of the City Clinical Hospital No. 50

    GILBERT SYNDROME

    ICD-10 code

    E80.4. Gilbert's syndrome.

    Gilbert's syndrome is a pigmentary hepatosis (simple familial cholemia, constitutional hyperbilirubinemia, idiopathic unconjugated hyperbilirubinemia, non-hemolytic familial jaundice) with an autosomal dominant type of inheritance, characterized by a moderate intermittent increase in the content of unbound (indirect) bilirubin in the blood. The syndrome was first described by French doctors A.N. Gilbert and P. Lereboullet in 1901

    This is the most common form of hereditary pigmentary hepatosis, which is detected in 2-5% of the population. Among Caucasians, the prevalence of the syndrome is 2-5%, among Mongoloids - 3%, among Negroids - 36%. The disease manifests itself in adolescence and continues throughout life. It occurs more often in males.

    Etiology and pathogenesis

    The syndrome is caused by a mutation in the gene UGT1A1, which codes for the enzyme uridine diphosphate glucuronyl transferase (UDPGT). The following links lie in the pathogenesis of the syndrome:

    Violation of the capture of bilirubin by microsomes of the vascular pole of hepatocytes;

    Violation of bilirubin transport with the help of glutathione-8-transferase, which delivers unconjugated bilirubin to hepatocyte microsomes;

    Inferiority of the microsomal enzyme UDFGT, with the help of which conjugation of bilirubin with glucuronic and other acids is carried out.

    In Gilbert's syndrome, the activity of UDPHT decreases only by 10-30% compared to the norm, the main importance is attached to the violation of the uptake of bilirubin by hepatocytes, which is associated with an abnormality in membrane permeability and a defect in the intracellular transport protein.

    Bilirubin exchange consists of its transport in the blood plasma, capture by the liver, conjugation, biliary excretion (Fig. 6-1).

    Approximately 250-300 mg of unconjugated bilirubin is produced daily in the human body: 70-80% of this amount is the result of the daily breakdown of erythrocyte hemoglobin; 20-30% is formed from heme proteins in the bone marrow or liver. In a healthy person, about 1% of circulating erythrocytes breaks down per day.

    Bilirubin, which was formed in reticuloendothelial cells, is a toxic compound. It is called unconjugated, indirect, or free, unbound bilirubin (due to the specifics of the reaction in its determination), and is water insoluble. That is why it is present in the blood plasma in the form of a compound with albumin. The albumin-bilirubin complex prevents the entry of bilirubin through the glomerular membrane into the urine.

    With the blood flow, indirect bilirubin enters the liver, where this form of bilirubin is converted into a less toxic form - direct (bound, conjugated) bilirubin. Both fractions make up total bilirubin.

    In the liver, unconjugated bilirubin is separated from albumin at the level of hepato-microvilli.

    Rice. 6-1. Exchange and conjugation of bilirubin

    cytes, its capture by intrahepatic protein. The conjugation of bilirubin with the formation of mono- and diglucuronides (conjugated bilirubin) is provided by UDFGT.

    The release of bilirubin into bile is the final stage of pigment metabolism and occurs through the cytoplasmic membranes of hepatocytes.

    In bile, conjugated bilirubin forms a macromolecular complex with cholesterol, phospholipids, and bile salts. Further, with bile, it enters the duodenum and small intestine, where it is transformed into urobilinogen, part of which is absorbed through the intestinal wall, enters the portal vein and is transferred with the bloodstream to the liver (enterohepatic circulation), where it is completely destroyed.

    The main amount of urobilinogen from the small intestine enters the large intestine, where, under the action of bacteria, it turns into stercobilinogen and is excreted in the feces. The amount of fecal stercobilinogen and stercobilin varies from 47 to 276 mg/day depending on body weight and sex.

    Less than 2% of bilirubin is excreted in the urine as urobilin.

    Clinical picture

    Mild jaundice, including scleral icterus, - main symptom diseases. In some cases, staining of the skin occurs (Fig. 6-2, a), especially the feet, palms, nasolabial triangle, armpits.

    Rice. 6-2. Gilbert's syndrome: a - the patient is a participant in a beauty contest; b - ultrasound: no changes; c - macropreparation of the liver with the accumulation of lipofuscin

    Patients should be viewed in daylight. Under electric lighting, skin color is distorted and can be misinterpreted.

    The yellowness of the skin and visible mucous membranes becomes clearly visible when the level of bilirubin in the blood serum reaches 43-50 µmol / l and above.

    Jaundice and hyperbilirubinemia are intermittent, so these symptoms are rarely permanent. Stress (for example, during exams or with great physical exertion caused by lifting weights) contributes to the appearance of jaundice and increased scleral icterus. Various surgeries, colds, poor diet, fasting, drinking alcoholic beverages, and certain types of medications contribute to the increase in symptoms. Total bilirubin in Gilbert's syndrome ranges from 21 to 51 µmol/l and periodically rises to 85-140 µmol/l.

    In half of the cases, dyspeptic complaints are observed: flatulence, stool disorders, nausea, belching, lack of appetite. The occurrence of jaundice may be accompanied by discomfort in the liver and weakness.

    The syndrome is associated with connective tissue dysplasia (especially common in the type of Marfan and Ehlers-Danlos syndromes).

    Diagnostics

    Diagnosis of the disease involves testing.

    Serum bilirubin test, which increases with fasting. The patient receives food for 2 days, the energy value of which does not exceed 400 kcal/day. The level of bilirubin in blood serum is determined on an empty stomach and after 48 hours. The test is positive if its rise is

    50-100%.

    Test with phenobarbital- the level of bilirubin decreases while taking phenobarbital due to the induction of conjugated liver enzymes.

    Test with nicotinic acid- intravenous administration of the drug causes an increase in the level of bilirubin due to a decrease in the osmotic resistance of erythrocytes.

    The result of a stool test for stercobilin is usually negative.

    Liver tests, in particular the levels of AST, ALT, alkaline phosphatase, etc., are usually within the normal range or slightly elevated. There may be an increase in total protein and dysproteinemia; prothrombin time - within the normal range. Markers of hepatitis B, C, D viruses are absent.

    Molecular diagnostics includes DNA analysis of the UDFGT gene.

    With the help of ultrasound of the abdominal organs, the size and condition of the liver parenchyma are determined (Fig. 6-2, b); size, shape, wall thickness, possible stones in the gallbladder and bile ducts.

    If there are indications to exclude chronic hepatitis (CH), liver cirrhosis, a percutaneous puncture biopsy of the liver is performed with a morphological assessment of the biopsy.

    Pathomorphology

    Morphological changes in the liver are characterized by fatty degeneration of hepatocytes and the accumulation of a yellowish-brown lipofuscin pigment in them, more often in the center of the lobules along the bile capillaries (Fig. 6-2, c).

    Differential Diagnosis

    Differential diagnosis is carried out with all types of hyperbilirubinemia (Table 6-1), hemolytic anemia, congenital cirrhosis of the liver and hepatitis, atresia of the bile ducts or small intestine, etc.

    Table 6-1. Differential diagnosis of hereditary hepatosis

    Treatment

    Patients, as a rule, do not need special treatment, since Gilbert's syndrome is not a disease, but an individual, genetically determined feature of the body. The main importance is the observance of the regime of study, work, rest, nutrition.

    Alcoholic drinks and fatty foods are highly undesirable, physical overload (professional sports), insolation, long breaks between meals, fluid restriction are not recommended.

    Components of therapy and prevention of exacerbations of Gilbert's syndrome:

    Diet therapy;

    Exclusion of provoking factors (infections, physical and mental stress, the use of hepatotoxic drugs and alcohol);

    Sun exposure contraindication.

    An episode of jaundice may resolve on its own without medication.

    If the level of bilirubin reaches 50 μmol / l and is accompanied by poor health, it is possible to take phenobarbital in a short course (1.5-2.0 mg / kg, or 30-200 mg / day in 2 doses for 2-4 weeks). Phenobarbital (luminal *) is part of drugs such as Corvalol *, Barboval *, Valocordin *, so sometimes they prefer to use these drugs (20-30-40 drops 3 times a day for 1 week),

    although the effect of such treatment is observed only in a small proportion of patients. Inducers of enzymes of the monooxidase system of hepatocytes, in addition to phenobarbital, include zixorin (flumecinol *), prescribed to adolescents at a dose of 0.4-0.6 g (4-6 capsules) 1 time per week or 0.1 g 3 times a day in within 2-4 weeks. Under the influence of these drugs, the level of bilirubin in the blood decreases, dyspeptic symptoms disappear, but in the course of treatment, lethargy, drowsiness, and ataxia occur. In such cases, these drugs are prescribed in minimal doses at bedtime, which allows them to be taken for a long time.

    Due to the fact that a significant part of patients develop cholecystitis and cholelithiasis, it is recommended to take infusions of choleretic herbs, periodically carry out tubages from sorbitol (xylitol), Karlovy Vary salt, etc. Hepatoprotectors are shown: ursodeoxycholic acid preparations (ursosan *, ursofalk *), phospholipids (Essentiale*), silibinin (karsil*), milk thistle fruit extract (legalon 70*), field artichoke leaf extract (chophytol*), liv 52*; choleretics: cholagol *, cholenzim *, allochol *, berberine *, holosas *; vitamin therapy, especially B vitamins.

    Removal of conjugated bilirubin is possible with the help of increased diuresis, the use of activated carbon adsorbing bilirubin in the intestine.

    Thermal physiotherapy on the liver area is contraindicated.

    Through phototherapy, the destruction of bilirubin fixed in tissues is achieved, thereby releasing peripheral receptors that can bind new portions of bilirubin, preventing its penetration through the blood-brain barrier.

    Prevention

    Prevention includes compliance with the regime of work, nutrition, rest. Significant physical exertion, fluid restriction, fasting and hyperinsolation should be avoided. The use of alcoholic beverages, hepatotoxic drugs is unacceptable.

    Gilbert's syndrome is not a reason to refuse vaccinations.

    Sanitation of chronic foci of infection and treatment of the existing pathology of the biliary tract are mandatory.

    Forecast

    The prognosis is favorable. Hyperbilirubinemia persists for life, but is not accompanied by progressive changes in the liver and increased mortality. When insuring life, such people are referred to the group of ordinary risk. During treatment with phenobarbital, the level of bilirubin decreases to normal values. Perhaps the development of inflammation in the biliary tract, cholelithiasis, psychosomatic disorders.

    Parents of children with this syndrome should consult a geneticist before planning another pregnancy.

    The same should be done if relatives of a couple planning to have children are diagnosed with this syndrome.

    FATTY LIVER

    ICD-10 code

    K76.0. Fatty degeneration of the liver.

    Hepatosis (liver steatosis, non-alcoholic steatohepatitis) is a group of liver diseases, which are based on metabolic disorders in hepatocytes and the development of dystrophic changes in liver cells, while inflammation is absent or mild.

    In recent years, a significant increase in the incidence of fatty degeneration of the liver has been observed, mainly associated with an increase in the prevalence of obesity. Among patients who underwent liver biopsy, approximately 7-9% of cases of hepatosis in Western countries and 1-2% in Japan are detected.

    Etiology and pathogenesis

    The causes of the disease are considered to be obesity, diabetes mellitus, dyslipidemia, rapid weight loss, lack of protein in the diet, congenital defects in β-oxidation of fatty acids, deficiency of α-1-antitrypsin, exposure to substances toxic to the liver, including alcohol, etc. Hepatosis can be both as an independent disease and as a manifestation of other diseases.

    Excess accumulation of fat in the liver tissue (in hepatocytes and Ito cells) may result from first impact(Fig. 6-3, a, d) - saturated with lipids, simple carbohydrates and high calorie content of food:

    Increasing the flow of free fatty acids to the liver;

    Decrease in the rate of β-oxidation of free fatty acids in liver mitochondria;

    Increasing the synthesis of fatty acids in the mitochondria of the liver;

    Decrease in the synthesis or secretion of very low density lipoproteins and the export of triglycerides in their composition.

    The result of a violation of the diet are insulin resistance and fatty liver.

    Second impact(see Fig. 6-3, d) implies a violation of the excretion of lipids from the liver, which occurs with a decrease in the amount of substances involved in their processing (protein, lipotropic factors). The formation of phospholipids, β-lipoproteins, lecithin from fats is disrupted. Tumor necrosis factor-α, endotoxin, and immune factors are important in pathogenesis. It is assumed that, regardless of the causes of steatosis, inflammatory-necrotic changes in the liver are based on universal mechanisms. Being highly reactive compounds, free fatty acids serve as a substrate for lipid peroxidation. The formed free radicals cause the destruction of lipid, protein components of membranes, liver receptors, etc., causing further changes in the liver.

    Classification

    There are pigmented and fatty hepatoses. Most often, the term "hepatosis" means fatty hepatosis (steatosis), since pigmentary hepatoses are much less common and are considered separately (see "Rare syndromes"), with the exception of Gilbert's syndrome.

    Clinical picture and diagnosis

    In the early stages, symptoms are minimal. As a rule, the course of the disease is latent, only an increase in the activity of hepatic transaminases and hepatomegaly are noted. In many patients, liver dysfunction is detected incidentally during examination for other diseases. There is a minimal or moderately pronounced activity of inflammation in the liver, detected by biochemical studies of blood serum. However, without treatment, a transition to cirrhosis of the liver can be observed, the phenomena of liver failure gradually increase.

    Fatty hepatosis is often concluded by ultrasound doctors on the basis of characteristic signs: a uniform increase in the liver, a diffuse increase in its echogenicity (sometimes pronounced) while maintaining its homogeneity, although with the progression of the process, a characteristic granularity of the parenchyma appears, indicating the onset of the development of steatohepatitis and hepatitis (Fig. 6-3b).

    Pathomorphology

    According to morphological studies, steatohepatitis is an excessive accumulation of triglycerides in the liver, which is accompanied by damage to cell membranes and other hepatocyte organelles, an inflammatory process, fibrosis up to liver cirrhosis (Fig. 6-3, c).

    Rice. 6-3. Functions and diseases of the liver: a - participation of the liver in lipid metabolism; b - ultrasound: hepatomegaly and increased echogenicity of the liver; c - macropreparation: liver steatosis; d - staging of liver pathology formation

    Treatment

    Diet therapy is a permanent and safe treatment for fatty liver disease.

    In order to normalize the oxidation of fatty acids in mitochondria, improve the transport of triglycerides from the liver, and reduce the processes of lipid peroxidation, drugs that improve lipid metabolism are prescribed - hepatoprotectors, vitamin B 12, folic acid, thioctic acid ( lipoic acid*) etc.

    Prevention

    basis primary prevention are a healthy lifestyle and a healthy diet (Figure 6-4). Sufficient physical activity is recommended.

    Rice. 6-4. Nutrition pyramid for fatty liver

    Dispensary observation is described below (see "Prevention of chronic hepatitis").

    Forecast

    With the exclusion of causative factors and timely treatment, recovery is possible, however, hepatosis can transform into chronic hepatitis and cirrhosis (see Fig. 6-3, d).

    CHRONIC HEPATITIS

    ICD-10 code

    K73. chronic hepatitis.

    Chronic hepatitis is a group of diseases accompanied by the development of diffuse inflammatory process in the liver, flowing for more than 6 months, confirmed by biochemical parameters, the results of a morphological study of the liver, as well as specific markers in the blood serum.

    The prevalence of CG has not been accurately established due to the large number of erased and asymptomatic forms, and the lack of population studies. Chronic viral hepatitis (CVH) caused by persistence of hepatitis B (29.2%), C (33.3%), chronic hepatitis B+C (16.7%), less often B+D (4.1%) %), D+G (no more than 2%). In 16.7% of cases, hepatitis of unknown etiology is detected.

    Classification

    The modern classification of hepatitis is presented in Table. 6-2. Taking into account the etiology, the following types of hepatitis are distinguished.

    . Specific viral hepatitis. The main forms of such hepatitis are hepatitis A, B and C. Hepatitis D is less common in the world. Hepatitis E remains a major problem in developing countries. Other hepatitis viruses (G, TTV, etc.) have also been described, but their clinical significance is low.

    . Nonspecific viral hepatitis are caused by a group of viruses that can affect both the liver and other organs. For example, a virus infectious mononucleosis(Epstein-Barr virus) selectively affects the cells of the reticuloendothelial system (clinically manifests itself in the form of tonsillitis, hypersplenism, hepatitis, etc.). Adenovirus causes pharyngoconjunctival fever, acute pneumonia, hepatitis. Herpes simplex virus is an AIDS-defining infection.

    Hepatitis - manifestation of an etiologically independent disease(with leptospirosis, pseudotuberculosis).

    Hepatitis associated with the use of drugs - toxic-allergic and medicinal hepatitis. Alcoholic hepatitis is a combined lesion with acetaldehyde and some other factor.

    . Nonspecific reactive hepatitis- the reaction of liver cells to the pathology of neighboring organs: pancreas, gallbladder, duodenum. Reactive hepatitis develops in patients with chronic pancreatitis, duodenal ulcer.

    Among autoimmune forms of chronic hepatitis 3 types of diseases have been identified (see Table 6-2).

    Row rare liver disease may have clinical and histological features of chronic persistent hepatitis:

    Primary biliary cirrhosis;

    Wilson-Konovalov disease;

    Primary sclerosing cholangitis;

    Deficiency of α-1-antitrypsin.

    The stage of fibrosis is established on the basis of a pathomorphological study of liver biopsy specimens (Table 6-3), approximately according to ultrasound data (Table 6-4).

    Table 6-2. Classification of Chronic Hepatitis (International Expert Group, Los Angeles, 1994)

    * It is determined based on the results of a histological examination of the liver tissue and approximately - according to the degree of ALT and AST activity (1.5-2 norms - minimal, 2-5 norms - low, 5-10 norms - moderate, above 10 norms - pronounced). ** Established on the basis of a morphological study of the liver and approximately - according to ultrasound.

    Table 6-3. Hepatitis histological activity index in points (Knodell R.. J. et al., 1994)

    Note: 1-3 points - the minimum degree of activity of chronic hepatitis; 4-8 - chronic hepatitis of moderate severity; 9-12 points - moderate chronic hepatitis; 13-18 points - severe chronic hepatitis.

    Table 6-4. Ultrasound criteria for the stages of liver fibrosis in chronic hepatitis in children

    Mixed hepatitis is established as the main diagnosis in the presence of simultaneous replication of 2 types of virus or more. With the replication of one and the integration of the other, the main hepatitis and concomitant hepatitis are established.

    Chronic viral hepatitis

    ICD-10 codes

    B18. Chronic viral hepatitis.

    818.0. Viral hepatitis B chronic with D-agent.

    818.1. Viral hepatitis B chronic without D-agent.

    818.2. Viral hepatitis C is chronic.

    818.8. Viral hepatitis chronic others.

    818.9. Viral hepatitis, chronic, unspecified. More than 70% of cases of chronic hepatitis are caused by hepatotropic viruses B, C and D. There are 350-400 million people infected with the hepatitis B virus worldwide, and about 1 million people die every year from hepatitis B viral (HBV) infection-related diseases . The prevalence of HBV infection in different countries ranges from 0.1 to 20%. The risk of transition from acute HBV infection to chronic decreases with age: with perinatal infection, it reaches 90%, with infection at the age of 1-5 years - 25-35%, and with adult infection - less than 10%.

    Etiology and pathogenesis

    The mechanism of formation, diagnosis of hepatitis B and C are shown in fig. 6-5. Viral hepatitis B (8 main genotypes - A-H) is found in blood and other biological fluids (semen, saliva, nasopharyngeal mucus), transmitted in four main ways:

    sexual;

    Perinatal (from mother to child in the prenatal period and in childbirth);

    Parenteral (through the blood);

    Horizontal (with close household contact or through infected common items; mainly observed in early childhood).

    In children, the main route of transmission of viral hepatitis B is perinatal. If a pregnant woman is a carrier of viral hepatitis B (and, in addition, HBeAg-positive), the probability of infection of a newborn with the development of a carriage of the virus is 90%. As adults, 25% of these children die of chronic liver failure or liver cancer. Although HBsAg, HBeAg, and HBV DNA are found in breast milk, the type of feeding does not affect the risk of HBV transmission. Other risk factors for hepatitis B infection include:

    Transfusion of blood and/or its components;

    Injection drugs, tattoos, piercings and other invasive skin procedures;

    Unprotected penetrative sex, especially anal and vaginal intercourse;

    Organ transplantation;

    Work in medical institutions;

    Hemodialysis.

    In regions with low endemicity of HBV infection, the highest incidence occurs in adolescents and young people. The most common routes of transmission of viral hepatitis B in these groups are sexual and parenteral (with unsafe drug injections, in particular, the reuse of disposable syringes).

    It's believed that chronic hepatitis B(CHB) is a primary chronic disease or a disease that occurs after an erased or subclinical form of an acute infection.

    Phases of CHB:

    Initial, or immune tolerance;

    Immune response (replicative), occurring with pronounced clinical and laboratory activity;

    Integrative;

    Carriage of HBsAg.

    Hepatitis B DNA virus (HBV DNA) itself does not cause cytolysis. Damage to hepatocytes is associated with immune responses that occur in response to circulating viral and hepatic antigens. In the 2nd phase of virus replication, virus antigens are expressed: HBsAg (surface), HBcAg (nuclear), HBeAg (Fig. 6-5, a), the immune response is more pronounced, which causes massive necrosis of the liver parenchyma and further virus mutation.

    Replication of the hepatitis B virus is also possible outside the liver - in the cells of the bone marrow, mononuclear cells, thyroid and salivary glands, which causes extrahepatic manifestations of the disease.

    Transmission routes chronic hepatitis C(CHC) are similar to those in CHB. Unlike viral hepatitis B, hepatitis C RNA virus has a direct hepatotoxic effect. As a result, viral replication and persistence in the body are associated with hepatitis activity and progression. Interestingly, viral hepatitis C is able to block apoptosis (programmed death) of cells affected by it in order to stay in the human body for a long time. Apoptosis is a normal process that rids the body of "worn out" or diseased cells. The protein encoded in the genome of viral hepatitis C, known as NS5A, blocks the opening of potassium channels in liver cells, protecting their “shelters” from natural death and thus lingering in the human body for a long time. The life cycle of viral hepatitis C is shown in Fig. 6-5, b.

    Rice. 6-5. Chronic hepatitis C and B: a - diagnosis of hepatitis C and B and dynamics of serological markers of hepatitis B; b - life cycle of hepatitis C virus

    Pathogen chronic hepatitis D(HGO) - an RNA-containing particle, the outer shell of which is represented by HBsAg. In the center of the particle is the antigen of the hepatitis D virus. The delta virus is able to multiply in liver cells only in the presence of viral hepatitis B, since its proteins are used to exit the cell of the delta virus particle. The disease proceeds simultaneously with viral hepatitis B by the type of co-or superinfection.

    Clinical picture

    The clinical picture of chronic hepatitis is mild and nonspecific. Asymptomatic course is observed in 25% of patients. The formation of chronic hepatitis occurs more often in the outcome of acute hepatitis, which occurs in the form of atypical (erased, anicteric, subclinical) forms and extremely rarely in manifest (icteric) forms of acute hepatitis. The acute phase of hepatitis and the appearance of clinical symptoms of the chronic form of the disease are separated by 5 years or more.

    Clinical manifestations of CG depend on the age of the child at the time of infection, the severity of morphological

    changes in the liver, phases of the infectious process (replication, integration), premorbid background. Children, unlike adults, cholestatic variant CG is rare; in the presence of cholestasis, it is necessary to exclude congenital pathology of intrahepatic or extrahepatic passages, deficiency of α-1-antitrypsin, cystic fibrosis. The main syndromes of the disease are given in table. 6-5.

    Table 6-5. The main syndromes of chronic viral hepatitis

    extrahepatic manifestations, associated with extrahepatic replication of the virus, are more characteristic of CHC, can manifest as recurrent dermatitis, hemorrhagic vasculitis, glomerulonephritis, arthropathy, thyroiditis, Sjögren's syndrome, pancreatopathies. Extrahepatic manifestations often develop at puberty, girls are characterized by the development of endocrine disorders, boys develop glomerulonephritis and other diseases.

    Extrahepatic manifestations include vascular changes (Table 6-6; Fig. 6-6). In children, they are much less common, their presence requires an extended study of liver function.

    Table 6-6. Vascular extrahepatic manifestations in chronic hepatitis

    Rice. 6-6. Vascular extrahepatic manifestations in chronic hepatitis: a - telangiectasia; b - capillaritis; c - palmar erythema

    Diagnostics

    specific methods. With the help of enzyme-linked immunosorbent assay (ELISA), the main markers of CG are detected, using the polymerase chain reaction (PCR) - DNA or RNA virus (Table 6-7; Fig. 6-5, a).

    Table 6-7. Marker diagnosis of chronic hepatitis B and C

    Serological markers viral hepatitis B is used to establish the diagnosis and stage of the disease.

    Antigens were presented above (see Fig. 6-5, a). Antibodies to the surface antigen of the virus (anti-HBsAg) appear in the blood after 3-6 months and persist for many years or possibly a lifetime. Their detection indicates either a previous infection or a previous vaccination.

    The nuclear antigen (HBcAg) usually does not circulate in the blood, but antibodies to it appear in the early stages of the disease, their titer quickly reaches a maximum, and then gradually decreases (but does not completely disappear). First, antibodies of the IgM class (anti-HBcAg IgM) appear, then IgG appear. Antigen E (HBeAg) appears in the blood for a short time at the onset of the disease, which is accompanied by the production of antibodies to it (anti-HBe).

    Chronic CHB infection is characterized by the presence of HBsAg and anti-HBcAg IgG in the blood.

    With CHC, in addition to viremia (HCV RNA), antibodies of the IgM and IgG classes are detected. Outside of an exacerbation, CHC RNA and anti-HCV IgM are not detected, but IgG class antibodies remain (see Tables 6-7).

    To non-specific methods include biochemical, immunological tests and instrumental studies.

    Biochemical tests do not carry information about the etiology of the disease, but reflect the nature of liver damage and the state of its function. These include:

    An increase in the level of liver enzymes: with chronic hepatitis, an increase in ALT is more pronounced than AST, which is associated with different localization of enzymes (ALT - in the cytoplasm, AST - in mitochondria), in cirrhosis, on the contrary, AST activity predominates over that of ALT; also characterized by an increase in such enzymes as lactate dehydrogenase, γ-glutamyl transpeptidase,

    AP;

    Violation of fat and pigment metabolism: an increase in the direct fraction of bilirubin, total cholesterol, β-lipoproteins, alkaline phosphatase activity, 5-nucleotidase;

    Violation of the protein-synthetic function of the liver: a decrease in total protein, an increase in thymol test, a decrease in sublimate test, a decrease in the level of prothrombin, persistent dysproteinemia due to an increase in globulin fractions, especially γ-globulins, and a decrease in albumin.

    Biochemical syndromes reflecting liver dysfunction are presented in Chapter 1 (see Tables 1-8, changes in protein fractions - Fig. 1-16, b).

    immunological tests. Characterized by a decrease in the levels of T-suppressors, an increase in the levels of serum immunoglobulins.

    Instrumental methods. Ultrasound of the liver is a mandatory research method for chronic hepatitis, since it allows you to visualize the liver, determine its size, identify liver cirrhosis and portal hypertension. Even with an asymptomatic course of the disease, using this method, it is possible to detect an increase in the liver, a change in the echogenicity of the parenchyma. Rheohepatography, puncture liver biopsy can be used.

    To date liver biopsy is the gold standard for diagnosing liver diseases (Fig. 6-7, a). During a biopsy, a piece of the liver with a diameter of about 1 mm is obtained using a special needle. The procedure is carried out under local or general anesthesia and under ultrasound control, since it is necessary to control the course of the needle, which makes the manipulation safe.

    The degree of CG activity is most often assessed using a semi-quantitative histological activity index, also known as the Knodell system, defined in points (see Tables 6-3). Histology of the biopsy (tissue sample) of the liver allows you to decide on the need and tactics of antiviral therapy.

    Pathomorphology

    Morphological examination of liver biopsy specimens already in the first months of life of a child with primary CG reveals signs of inflammation that persist for many years, as well as progressive fibrosis with the formation of liver cirrhosis.

    Rice. 6-7. Diagnosis of chronic hepatitis: a - biopsy technique; histological picture: b - CHB (staining with hematoxylineosin; χ 400); c - CHC (x 400).

    CHB is characterized by necrosis (Fig. 6-7, b); a pathognomonic sign in CHC is vacuolization of the nuclei of hepatocytes, the so-called opaque vitreous hepatocytes, as well as their stepwise necrosis (Fig. 6-7, c).

    Differential Diagnosis

    Treatment

    AT replication phase (exacerbation) shows hospitalization in a specialized department, bed rest, strict diet therapy.

    Basic therapy includes appointment antiviral drugs. Indications for its appointment:

    The presence of markers of active hepatitis replication;

    The level of ALT is more than 2-3 times higher than normal;

    Absence of cholestasis and signs of liver cirrhosis with decompensation;

    Absence of severe concomitant diseases in the stage of decompensation;

    Absence of autoimmune diseases, immunodeficiency, mixed hepatitis.

    Interferon inducers characterized by low toxicity and the absence of side effects, unlike interferon preparations, thanks to their use, it is possible to significantly increase life expectancy in children and adults (Fig. 6-8).

    Rice. 6-8. Chronic hepatitis (course and treatment): a - antiviral treatment of children and adults with chronic viral hepatitis B and C and years of life gained; b - natural course of hepatitis B

    Interferon preparations contraindicated in psychosis, epidemic syndrome, severe neutro- and thrombocytopenia, autoimmune diseases (AIH, thyroiditis, etc.), decompensated liver cirrhosis and kidney disease, heart pathology in the decompensation stage.

    Interferon-a-2b (reaferon*, roferon*, neuroferon*) - a lyophilizate for the preparation of a suspension for oral administration - is prescribed 30 minutes before a meal, 1-2 ml of chilled boiled water is added to the contents of the vial before use. The drug is administered in injections for CHB at a dose of 5 million IU / m 2, for CHC - 3 million IU / m 2 of body surface area three times a week (1 time with an interval of 72 hours) s / c or / m. The calculated dose of interferon is initially administered for 3 months. After this period, a control study is carried out (RNA or DNA of the virus, activity). If there is no clear positive dynamics of these indicators (the disappearance of RNA, virus DNA from the blood, a decrease in ALT), it is better to stop treatment according to this scheme or switch to combination therapy. But if there is a decrease in ALT activity, a drop in the concentration of RNA, DNA of the virus in the blood, treatment according to the selected scheme is continued for another 3 months, followed by a control

    laboratory research. With positive dynamics in CHC, treatment is still continued for 3 months to consolidate the results of treatment. Thus, the course of treatment for CHB is 6 months, for CHC - 9-12 months.

    In pediatric practice, viferon is used (a combination of α-interferon with membrane stabilizers), which is available in rectal suppositories. Doses for children: up to 3 years - 1 million IU, over 3 years - 2 million IU 2 times a day with an interval of 12 hours 3 times a week. In patients treated according to the protocol program using viferon, the effectiveness of treatment is assessed according to the above principles. If there is no positive effect in this category of patients during a control study 3 months after the start of therapy, then viferon can be replaced with reaferon*, roferon*.

    The α-interferon inducer meglumine acridone acetate (cycloferon*) is administered for chronic hepatitis at 6-10 mg/kg per day, 10 injections daily, then 3 times a week for 3 months as a complex therapy.

    The antiviral drug tilorone (amiksin) is prescribed to children over 7 years old in tablets of 0.125 orally after meals, the first 2 days daily, then 125 mg every other day - 20 tablets, then 125 mg once a week for 10-20 weeks. The course of treatment for CHA is 2-3 weeks, for CHB - 3-4 weeks.

    In CHB against the background of virus replication, the antiviral chemotherapy drug lamivudine (Zeffix, Epivir*) is recommended in oral solution and tablets. It is dosed at 3 mg / kg per day for children from 3 months, but not more than 100 mg orally 1 time per day for a course of 9-12 months. Tablets of 100 mg 1 time per day are prescribed to adolescents (16 years and older) orally, regardless of food intake.

    In general, interferon therapy is effective in 40% of patients with CHB and in 35% of patients with CHC, but in 10-30% of patients after the end of treatment, relapses of the disease are possible.

    In severe form of CG, prescribe glucocorticoids: prednisolone or methylprednisolone in tablets of 0.001; 0.0025 and 0.005 mg, 1-2 mg / kg per day in 2 divided doses, without taking into account the daily rhythm. After achieving remission, the dose is reduced by 5-10 mg to a maintenance dose of 0.3-0.6 mg/kg per day: 10-15 mg/day of prednisolone or 8-12 mg/day of methylprednisolone.

    Criteria for the effectiveness of treatment:

    . biochemical - the most informative is the determination of the level of ALT, and during treatment, ALT activity should be determined throughout the course and for another 6 months after withdrawal, and then every 3-6 months for 3 years;

    Virological - determination of RNA, DNA of the virus using PCR;

    Histological ones are the most informative for evaluating the effectiveness of treatment, but in practice they are not always realizable, especially in pediatrics.

    Biochemical remission at the end of treatment involves the normalization of enzyme levels immediately after the end of the course of therapy; complete remission- normalization of AST and ALT levels and the disappearance of RNA, virus DNA immediately after treatment; stable biochemical remission- preservation normal value transaminases 6 months or more after discontinuation of therapy; stable complete remission- preservation normal levels AST and ALT and the absence of RNA, virus DNA 6 months after treatment.

    If a stable complete remission is achieved, it is recommended to continue monitoring the patient for at least 2 years with a frequency of 1 every six months. In the remission phase (integration phase of CVH), antiviral therapy is usually not carried out, the treatment consists of organizing a diet, regimen, connecting probiotics, enzymes, herbal remedies, laxatives according to indications to prevent gastrointestinal dysfunction and intestinal autointoxication.

    Accompanying therapy- This is a symptomatic and pathogenetic treatment.

    In order to relieve cholestasis, ursodeoxycholic acid preparations (ursosan *, urdox *, ursofalk *) are used as monotherapy in the non-replicative phase of hepatitis, in the replicative phase - in combination with interferons up to 6-12 months, 10 mg / kg once a day before bedtime.

    Hepatoprotectors that have the ability to protect hepatocytes are prescribed in courses of up to 1.5-2 months. Repeated course - in 3-6 months according to indications.

    Artichoke leaf extract (chophytol *) is a herbal remedy that has hepatoprotective and choleretic effects. Hofitol * is prescribed for children over 6 years old, 1-2 tablets or 1/4 tsp. oral solution 3 times a day before meals, adolescents - 2-3 tablets or 0.5-1 tsp. solution 3 times a day, course - 10-20 days. Solution for intramuscular or intravenous slow administration - 100 mg (1 ampoule) for 8-15 days; average doses can be significantly increased, especially in hospital treatment.

    Hepatoprotector "Liv 52 *" is a complex of biologically active substances vegetable origin; it is prescribed for children over 6 years old, 1-2 tablets 2-3 times a day, for adolescents - 2-3 tablets 2-3 times a day.

    Ademetionine (Heptral *) is a hepatoprotector that has choleretic and cholekinetic, as well as some antidepressant effects. Children are prescribed with caution inside, in / m, in / in. In intensive care in

    the first 2-3 weeks of treatment - 400-800 mg / day in / in slowly or / m; the powder is dissolved only in the special supplied solvent (L-lysine solution). For maintenance therapy - 800-1600 mg / day inside between meals, without chewing, preferably in the morning.

    Prevention

    Main preventive actions should be aimed at preventing infection with hepatitis viruses, therefore, early detection of patients with erased forms diseases and their appropriate treatment. Carriers of HBsAg require regular (at least once every 6 months) monitoring of biochemical and virological parameters in order to prevent activation and replication of the virus.

    For vaccination against hepatitis B, recombinant vaccines are used: Biovak B *, Engerix B *, Euvax B *, Shanvak-B *, etc. RD for newborns and children under 10 years old - 10 mcg (0, 5 ml suspension), for children over 10 years old - 20 mcg (1 ml suspension).

    For newborns born to mothers who are carriers of hepatitis B, it is recommended to administer hepatitis B immunoglobulin simultaneously with the vaccine, and the drugs should be administered at different sites. In accordance with the rules existing in the Russian Federation, vaccination of this category of children is carried out four times according to the scheme: 0 (on the day of birth) -1 - 2-12 months of life. Against hepatitis B, adolescents aged 11-13 years old must be vaccinated according to the same scheme.

    Widely vaccinate medical workers and persons at risk for hepatitis B infection. Vaccination leads to a gradual decrease in the level of infection of the population of the Russian Federation with the hepatitis B virus.

    A vaccine against hepatitis C has not yet been developed, and therefore the prevention of hepatitis C is built on the suppression of all possibilities of parenteral (including transfusion) infection.

    Clinical supervision is described below.

    Forecast

    The chance of a complete recovery is low. With chronic hepatitis B, a long-term persistence of the causative virus occurs, possibly a combination with an active pathological process. On average, after 30 years, 30% of patients with chronic active hepatitis B develop cirrhosis of the liver. Within 5 years, approximately one in four patients with hepatitis B cirrhosis will develop liver decompensation, and another 5-10% of patients will develop liver cancer (see Fig. 6-8). Without treatment, approximately 15% of patients with cirrhosis die within 5 years. In 1-1.5% of cases, cirrhosis is formed, and in the remaining 89%, a long-term remission occurs with HBsAg carriage. With ΧΓD, the prognosis is unfavorable: in 20-25% of cases, the process flows into cirrhosis of the liver; release from the pathogen does not occur. CHC flows slowly, gently, without cessation of viremia for many years, with a periodic increase in transaminase activity and with a pronounced tendency to fibrosis. As the process progresses, cirrhosis of the liver and hepatocellular carcinoma develop.

    AUTOIMMUNE HEPATITIS

    ICD-10 code

    K75.4. autoimmune hepatitis.

    AIH is a progressive hepatocellular inflammation of the liver of unknown etiology, characterized by the presence of periportal hepatitis, frequent association with other autoimmune diseases, an increase in the concentration of immunoglobulins (hypergammaglobulinemia) and the presence of autoantibodies in the blood.

    Like other autoimmune diseases, AIH is more common in females, with an overall incidence of approximately 15-20 cases per 100,000 population. In childhood, the proportion of AIH among chronic hepatitis ranges from 1.2 to 8.6%, observed at the age of 6-10 years. The ratio of girls and boys is 3-7:1.

    Etiology and pathogenesis

    The pathogenetic mechanism of the development of AIH is based on a congenital defect in HLA membrane receptors. Patients have a defect in the function of T-suppressors linked by the HLA haplotype, resulting in uncontrolled synthesis of IgG class antibodies by B-lymphocytes that destroy the membranes of normal hepatocytes, and pathological immune reactions against their own hepatocytes develop. Often, not only the liver is involved in the process, but also large glands of external and internal secretion, including the pancreas, thyroid, and salivary glands. As the main factor in the pathogenesis of AIH, genetic predisposition (immunoreactivity to self-antigens) is considered, which, however, is not sufficient in itself. It is believed that triggering agents (triggers) are necessary for the implementation of the process, among which viruses (Epstein-Barr, measles, hepatitis A and C) and some drugs (for example, interferon drugs) and adverse environmental factors are considered.

    Rice. 6-9. AIH pathogenesis

    The pathogenesis of AIH is shown in Fig. 6-9. The effector mechanism of hepatocyte injury seems to be more related to autoantibody response to liver-specific hepatocyte antigens than to direct T-cell cytotoxicity.

    Classification

    There are currently 3 types of AIH:

    - type 1- the classic version, it accounts for 90% of all cases of the disease. Detect antibodies to smooth muscle cells (Smooth Muscle Antibody- SMA) and nuclear antigens (liver-specific

    squirrel - Antinuclear Antibodies- ANA) in a titer of more than 1:80 in adolescents and more than 1:20 in children;

    -type 2- accounts for about 3-4% of all cases of AIH, most of the patients are children from 2 to 14 years old. Detect antibodies to liver and kidney microsomes (Liver Kidney Microsomes- LKM-1);

    -type 3- characterized by the presence of antibodies to soluble liver antigen (Soluble Liver Antigen- SLA) and hepato-pancreatic antigen (LP).

    Some features of AIG, taking into account the types, are presented in Table. 6-8.

    Table 6-8.Classification and features of types of AIH

    Clinical picture

    The disease in 50-65% of cases is characterized by the sudden onset of symptoms similar to those of viral hepatitis. In some cases, it begins gradually and is manifested by increased fatigue, anorexia and jaundice. Other symptoms include fever, arthralgia, vitiligo (pigmentation disorder characterized by loss of melanin pigment in patches of skin) and nosebleeds. The liver protrudes from under the edge of the costal arch by 3-5 cm and thickens, there is splenomegaly, the abdomen is enlarged in size (Fig. 6-10, a). As a rule, extrahepatic signs of chronic liver pathology are detected: spider veins, telangiectasia, palmar erythema. Some patients have a Cushingoid appearance: acne, hirsutism and pink striae on the thighs and abdomen; 67% are diagnosed with other autoimmune diseases: Hashimoto's thyroiditis, rheumatoid arthritis, etc.

    Diagnostics

    Diagnosis is based on the detection of syndromes of cytolysis, cholestasis, hypergammaglobulinemia, an increase in the concentration of IgG, hypoproteinemia, a sharp increase in ESR, and is confirmed by the detection of autoantibodies against hepatocytes.

    characteristic hypersplenism syndrome, its signs:

    Splenomegaly;

    Pancytopenia (decrease in the number of all blood cells): anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia (with a sharp degree of severity, a bleeding syndrome appears);

    Compensatory hyperplasia of the bone marrow.

    In diagnostics, instrumental research methods (scanning, liver biopsy, etc.) are of unconditional importance.

    Pathomorphology

    Morphological changes in the liver in AIH are characteristic but nonspecific. CG, as a rule, turns into multilobular cirrhosis of the liver (Fig. 6-10, b); characterized by a high degree of activity: periportal

    necrosis, porto-portal or centroportal bridging necrosis, less often - portal or lobular hepatitis, predominantly lymphocytic infiltration with a large number of plasma cells, the formation of rosettes (Fig. 6-10, c).

    Rice. 6-10. AIH: a - a child with an outcome in liver cirrhosis; b - macropreparation: macronodular cirrhosis; c - micropreparation: histological picture (staining with hematoxylin-eosin; χ 400)

    Differential Diagnosis

    Differential diagnosis is carried out with CHB, cholecystitis, Wilson-Konovalov disease, drug-induced hepatitis, α-1-antitrypsin deficiency, etc.

    Distinguish between definite and probable AIH. The first variant is characterized by the presence of the above indicators, including an increase in autoantibody titers. In addition, there are no viral markers in the blood serum, bile duct damage, copper deposition in the liver tissue, no indications for blood transfusions and the use of hepatotoxic drugs.

    The probable variant of AIH is justified when the present symptoms suggest AIH, but are not sufficient to make a diagnosis.

    Treatment

    The basis is immunosuppressive therapy. Assign prednisolone, azathioprine, or combinations thereof, which allow to achieve clinical, biochemical and histological remission in 65% of patients within 3 years. Treatment is continued for at least 2 years until remission is achieved for all criteria.

    Prednisolone is prescribed at a dose of 2 mg / kg (maximum dose - 60 mg / day) with a gradual decrease by 5-10 mg every 2 weeks under weekly monitoring of biochemical parameters. In the absence of normalization of transaminase levels, azithioprine is additionally prescribed at an initial dose of 0.5 mg/kg (maximum dose is 2 mg/kg).

    A year after the onset of remission, it is desirable to cancel immunosuppressive therapy, but only after a control puncture liver biopsy. Morphological examination should indicate the absence or minimal activity of inflammatory changes.

    With the ineffectiveness of glucocorticoid therapy, cyclosporine (sandimum neoral *) is used for oral administration from the first year of life, which is released in a solution of 100 mg in 50 ml in a vial, capsules of 10, 25, 50 and 100 mg,

    prescribe the drug at a dose of 2-6 mg / kg per day (no more than 15 mg / m 2 per week). Cyclophosphamide (cyclophosphamide *) is prescribed intravenously at a dose of 10-12 mg / kg 1 time in 2 weeks, then in tablets of 0.05 g, 15 mg / kg 1 time in 3-4 weeks, the course dose is not more than 200 mg/kg.

    In 5-14% of patients, primary resistance to treatment is observed. They are primarily subject to consultation at liver transplant centers.

    Prevention

    Primary prevention has not been developed, the secondary consists in early diagnosis, dispensary observation of patients (described below) and long-term immunosuppressive therapy.

    Forecast

    The disease without treatment continuously progresses and does not have spontaneous remission - cirrhosis of the liver is formed. In AIH type 1, glucocorticoids are more often effective and the prognosis is relatively favorable: in many cases, prolonged clinical remission can be achieved. In AIH type 2, the disease usually progresses rapidly to cirrhosis. Type 3 is clinically poorly defined and its course has not been studied.

    With the ineffectiveness of immunosuppressive therapy, patients are shown liver transplantation, after which the 5-year survival rate is more than 90%.

    drug-induced hepatitis

    ICD-10 code

    K71. drug-induced hepatitis.

    Drug-induced hepatitis is a toxic liver injury, including idiosyncratic (unpredictable) and toxic (predictable) drug-induced liver disease, associated with the intake of hepatotoxic drugs and toxic substances.

    Etiology and pathogenesis

    The liver plays an important role in the metabolism of xenobiotics (foreign substances). The group of enzymes located in the endoplasmic reticulum of the liver, known as cytochrome P450, is the most important family of enzymes in liver metabolism. Cytochrome P450 absorbs about 90% of toxic and medicinal products.

    Often the liver becomes a target for their damaging effects. There are direct and indirect types of liver damage.

    Direct type of liver damage depends on the dose of the drug and is due to the action of the drug itself on liver cells and its organelles. The drugs with obligate dose-dependent hepatotoxic effects include paracetamol and antimetabolites, leading to necrosis of hepatocytes. Direct liver damage can also be caused by tetracycline, mercaptopurine, azathioprine, androgens, estrogens, etc.

    Indirect type of liver damage, not dependent on the dose of drugs, observed when taking nitrofurans, rifampicin, diazepam, meprobamate, etc. This type reflects the individual reaction of the child's body as a manifestation of hypersensitivity to drugs.

    The liver is involved in the metabolism of various xenobiotics through biotransformation processes, which are divided into two phases.

    . First phase- oxidative reactions taking place with the participation of cytochromes P450. During this phase, active metabolites may be formed, some of which have hepatotoxic properties.

    . Second phase during which the conjugation of previously formed metabolites with glutathione, sulfate or glucuronide occurs, resulting in the formation of non-toxic hydrophilic compounds that are excreted from the liver into the blood or bile.

    A special place among toxic liver damage is occupied by medicinal, or drug-induced, hepatitis. Their formation occurs more often as a result of uncontrolled use of drugs (Fig. 6-11, a). Almost any drug can cause liver damage and the development of hepatitis of varying severity.

    Toxins can be conditionally divided into household and industrial. Allocate industrial poisons organic nature(carbon tetrachloride, chlorinated naphthalene, trinitrotoluene, trichlorethylene, etc.), metals and metalloids (copper, beryllium, arsenic, phosphorus), insecticides (dichlorodiphenyltrichloroethane - DDT, karbofos, etc.).

    Rice. 6-11. Drug-induced hepatitis: a - the formation of drug-induced hepatitis with necrosis of hepatocytes; b - histological picture of drug-induced hepatitis after treatment acute leukemia(staining with hematoxylin-eosin; χ 400)

    Particularly severe forms of hepatocyte damage develop when poisoned with substances such as paracetamol, pale toadstool poison, white phosphorus, carbon tetrachloride, and all industrial poisons.

    Clinical picture

    Typical forms of liver damage with hepatotoxic effects of drugs are presented in Table.

    6-9.

    Table 6-9. The most common hepatotoxic drug effects

    Drug reactions can be transient, hCG are observed infrequently. Liver function tests may return to normal within a few weeks (up to 2 months) after discontinuation of drugs, but in cholestatic hepatitis this period may increase up to 6 months. Jaundice always indicates more severe liver damage, possibly the development of acute liver failure.

    Diagnostics

    The basis of the diagnosis of drug-induced liver damage is a carefully collected anamnesis of the drugs used, prescribed or used as self-medication. Usually the time interval between taking the drug and the onset of the disease is from 4 days to 8 weeks.

    A biopsy may be indicated if pre-existing liver disease is suspected or if blood chemistry (liver function tests) have not returned to normal after discontinuation of the drug.

    Pathomorphology

    Discomplexation of hepatic beams, severe protein (granular and balloon) dystrophy of hepatocytes, polymorphism of hepatocyte nuclei, dystrophic and necrobiotic changes in the nuclei of hepatocytes are observed (Fig. 6-11, b).

    Differential Diagnosis

    The possibility of toxic effects of drugs should be taken into account in the differential diagnosis of liver failure, jaundice. It is necessary to exclude other causes: viral hepatitis, diseases of the bile ducts, etc. In rare cases, it is necessary to carry out differential diagnosis with congenital metabolic diseases that can cause liver damage, type I glycogenosis (Girke's disease),

    Type III (Cori's disease), Type IV (Andersen's disease), Type VI (Hers disease). These diseases occur due to excessive accumulation of glycogen in the liver cells. Chronic liver damage of drug genesis should also be differentiated from lipidosis: Gaucher's disease (based on the accumulation of nitrogen-containing cerebrosides in the reticulohistiocytic cells) and Niemann-Pick disease (resulting from the accumulation of phospholipids, mainly sphingomyelin, in the cells of the reticuloendothelial system). It is also necessary to exclude galacto- and fructosemia.

    Treatment

    A mandatory and main condition for treatment is the complete rejection of the use of a hepatotoxic drug.

    A high-calorie (90-100 kcal / kg per day) diet rich in proteins (2 g / kg per day) and carbohydrates helps to restore the functional state of the liver. For therapeutic purposes, essential phospholipids are recommended, which have membrane-stabilizing and hepatoprotective effects, as well as inhibitors of lipid peroxidation processes. Thioctic acid is also prescribed

    lota (lipoic acid *, lipamide *), which reduces the toxic effects of drugs due to its antioxidant effect; children over 12 years of age - flavonoid silibinin (karsil *) 5 mg / kg in 3 divided doses (do not chew pills, take after meals with plenty of water).

    Forecast

    The prognosis depends on how quickly the drug that caused liver damage is stopped. Usually, clinical manifestations and changes in biochemical parameters normalize within a few days, rarely weeks.

    The prognosis is always serious when a picture of chronic liver damage with hepatocellular insufficiency is formed.

    Prevention of chronic hepatitis

    Primary prevention has not been developed, the secondary one consists in early recognition and adequate treatment of children with acute viral hepatitis.

    The widespread introduction of vaccination against hepatitis A and B will solve the problem of not only acute, but also chronic hepatitis.

    CIRRHOSIS OF THE LIVER

    ICD-10 codes

    K71.7. Toxic liver damage with fibrosis and cirrhosis of the liver.

    K74. Fibrosis and cirrhosis of the liver cryptogenic. K74.3. Primary biliary cirrhosis. K74.4. Secondary cirrhosis of the liver. K74.5. Biliary cirrhosis, unspecified. K74.6. Other and unspecified cirrhosis of the liver. P78.3. Cirrhosis is congenital.

    Cirrhosis of the liver is a chronic progressive disease characterized by degeneration and necrosis of the hepatic parenchyma, accompanied by its nodular regeneration, diffuse proliferation of connective tissue. It is a late stage of various diseases of the liver and other organs, in which the structure of the liver is disturbed, and liver functions are not fully performed, resulting in liver failure.

    Liver cirrhosis should be distinguished from its fibrosis. Fibrosis - focal proliferation of connective tissue in various liver lesions: abscesses, infiltrates, granulomas, etc.

    In economically developed countries, cirrhosis of the liver occurs in 1% of the population, is one of the 6 main causes of death in patients aged 35 to 60 years. Every year, 40 million people die in the world from viral cirrhosis of the liver and hepatocellular carcinoma, which develops against the background of carriage of the hepatitis B virus. It is more often observed in males, the ratio with the female sex is 3:1.

    Biliary atresia is one of the common causes biliary cirrhosis in infants, the incidence is 1 in 10,000-30,000 newborns.

    Etiology and pathogenesis

    Many diseases of the liver and other organs, long-term use of drugs (see Fig. 6-11, a, 6-12, a), etc. lead to cirrhosis of the liver. In addition, other diseases are important in the formation of cirrhosis:

    Primary biliary cirrhosis;

    Hereditary metabolic disorders (hemochromatosis, hepatolenticular degeneration, galactosemia, α-1-antitrypsin deficiency, etc.);

    Violation of the venous outflow from the liver (Budd-Chiari syndrome, veno-occlusive disease, severe right ventricular heart failure), etc.

    Atresia of the biliary tract refers to developmental anomalies, which in most cases are associated with intrauterine hepatitis, often caused by one of the reoviruses. In some children, the occurrence of this malformation is due to adverse factors that acted on the 4-8th week of intrauterine life. Usually these children have malformations of other organs (often kidneys, heart, spine). Some children have an association with trisomy on the 13th and 18th pairs of chromosomes. Atresia is characterized by complete closure of intra-, extrahepatic bile ducts in various variants. More often (in 70-80% of cases) intrahepatic form of atresia occurs.

    One of the main signs and complications of liver cirrhosis is portal hypertension syndrome which occurs due to an increase in pressure in the portal vein (a vein that brings blood from the abdominal organs to the liver) of more than 5 mm Hg. As a result high blood pressure in the portal vein, blood cannot flow from the abdominal organs and blood stagnation occurs in these organs (Fig. 6-12, b).

    Exemplary cellular composition liver: 70-80% - hepatocytes, 15% - endothelial cells, 20-30% - Kupffer cells (macrophages), 5-8% - Ito cells (Fig. 6-13, a). Ito cells(synonyms: liver stellate cells, fat-storing cells, lipocytes), located in the perisinusoidal space of Disse, play a key role in the pathogenesis of liver cirrhosis. Being the main cells of the connective tissue in the liver, they form the extracellular matrix, accumulating lipids normally. When the liver is damaged, Ito cells begin to produce type I collagen and cytokines, acquiring fibroblast-like properties (Fig. 6-13b). This process occurs with the participation of hepatocytes and Kupffer cells.

    Rice. 6-12. Cirrhosis of the liver: a - etiological factors; b - the portal system of the liver and the mechanism of formation of portal hypertension

    The pathogenesis of liver cirrhosis is shown in Fig. 6-13, b, but in approximately 10-35% of patients, the etiology and pathogenesis of liver cirrhosis remain unknown.

    1 Rice. 6-13. a - part of the hepatic lobule and its cellular composition; b - pathogenesis of liver cirrhosis

    Liver changes in cirrhosis are usually diffuse, only in biliary cirrhosis they can be focal. The death of hepatocytes associated with inflammation and fibrosis leads to disruption of the normal liver architectonics: the loss of the normal hepatic vasculature with the development of portocaval shunts and the formation of regeneration nodes of preserved hepatocytes (Fig. 6-14, a), rather than normal hepatic lobules detected in autopsy material or in vivo using MRI (Fig. 6-14, b).

    Rice. 6-14. Changes in the liver in cirrhosis: a - macropreparation of micronodular cirrhosis of the liver; b - MRI of the liver: the arrow indicates the node of regeneration

    Classification

    Allocate atresia of the extrahepatic biliary tract (without or in combination with atresia of the gallbladder), atresia of the intrahepatic bile ducts (without or in combination with atresia of the extrahepatic biliary tract), total atresia. The classification of liver cirrhosis is presented in Table. 6-10.

    Table 6-10. Classification of liver cirrhosis

    Clinical picture

    In primary biliary cirrhosis, which is manifested by inflammation of the bile ducts of the liver with a violation of the outflow of bile, jaundice, itching, fever and other symptoms are observed. Biliary cirrhosis associated with congenital atresia of the biliary tract is formed quickly, leading to death in the absence of surgical intervention for health reasons.

    Alcoholic cirrhosis of the liver develops in persons who consume alcoholic beverages in excessively large doses for a long time; it is not considered in childhood hepatology.

    Cirrhosis of the liver in older children develops slowly and may be asymptomatic at first. The signs indicated in the table. 6-11, as a rule, develop gradually and are invisible to a child who has been suffering from a chronic disease of the liver or other organs for a long time, and to his parents.

    Hepatomegaly is observed at the onset of the disease. Gradual destruction of hepatocytes, fibrosis as the underlying disease progresses lead to reduction in the size of the liver. Especially characteristic is a decrease in the size of the liver in cirrhosis caused by viral and autoimmune hepatitis.

    Table 6-11. Signs of cirrhosis of the liver

    Complications of liver cirrhosis are portal hypertension syndrome (Table 6-12), varicose veins of the lower extremities, bleeding from the dilated veins of the esophagus, hepatic coma.

    Table 6-12. Diagnosis of Portal Hypertension Syndrome

    Varicose veins- a complication of cirrhosis of the liver, manifested by pain in the limbs, visible and significant enlargement of the veins. Bleeding from dilated veins of the esophagus manifested by the release of blood from the mouth and / or blackening of the stool. hepatic coma- brain damage that develops as a result of the accumulation of a large amount of toxic substances in the blood, as a rule, develops with decompensated cirrhosis; the main signs of the syndrome of hepatocellular insufficiency are presented in table. 6-13.

    Table 6-13. Signs of hepatocellular insufficiency syndrome

    Diagnostics

    AT biochemical analysis identify initially syndromes of cytolysis, cholestasis, inflammation, later - hepatodepressive syndrome (see Tables 1-8).

    Ultrasound describes micronodular (Fig. 6-15, a) or macronodular (Fig. 6-15, b) types of liver cirrhosis. Histological synonyms for these names:

    Small-nodular cirrhosis - the formation of small nodules (about 1 mm in diameter) is characteristic;

    Large-nodular cirrhosis - in areas of previous destruction of the hepatic architectonics, large fibrous scars are detected.

    Pathomorphology

    A classic liver macropreparation, clearly representing biliary cirrhosis of the liver, is shown in Fig. 6-15, c.

    During the life of a child, only a biopsy can accurately indicate liver cirrhosis, in which severe dystrophic changes in hepatocytes, cholestasis, foci of proliferation of connective tissue (fibrous nodes), between which islets are located normal liver cells (Fig. 6-15, d).

    Differential Diagnosis

    Treatment

    The main principles of treatment of cirrhosis of the liver are as follows.

    Elimination of the causes that led to cirrhosis (etiotropic treatment): antiviral therapy(viral hepatitis), withdrawal (alcoholic cirrhosis), drug withdrawal (drug-induced hepatitis).

    Rice. 6-15. Cirrhosis of the liver according to ultrasound: a - micronodular; b - macronodular: congenital atresia of the bile ducts with the formation of cirrhosis: c - macropreparation; d - micropreparation (staining with hematoxylin-eosin; χ 400)

    Diet therapy.

    Therapy of developed complications of liver cirrhosis: symptomatic treatment of hepatic encephalopathy, portal hypertension syndrome, etc.

    Pathogenetic: removal of excess iron and copper (hemochromatosis, Wilson-Konovalov disease), immunosuppressive therapy (AIH), treatment of cholestasis (primary biliary cirrhosis).

    With established diagnosis biliary atresia surgical treatment: choledochojejunostomy or protoenterostomy (Kasai operation - the creation of a direct anastomosis between the decapsulated opened surface of the liver in

    gate area and intestines), transplantation of a part of the liver. Before surgery, treatment is supportive. Glucocorticoids are ineffective, as are other drugs. At the same time, vitamin K should be administered parenterally once a week, periodically taking courses of hepatoprotectors, vitamins E, D.

    Treatment of complications of liver cirrhosis

    Strict bed rest;

    Hyponatrium diet: with minimal and moderate ascites - restriction of salt intake to 1.0-1.5 g / day; with intense ascites - up to 0.5-1.0 g / day;

    Restriction of fluid intake to 0.8-1.0 liters per day;

    Diuretic therapy: aldosterone antagonists and natriuretics;

    Therapeutic paracentesis (3-6 l) with intravenous administration of albumin solution (at the rate of 6-8 g per 1 l of removed ascitic fluid);

    Ultrafiltration with a peritoneal-venous shunt, transjugular intrahepatic portosystemic shunt;

    Liver transplant.

    Diuretics. Hydrochlorothiazide (hypothiazid *) in tablets and capsules is prescribed orally for children from 3 to 12 years old, 1-2 mg / kg per day in 1 dose. Hypokalemia can be avoided by the use of drugs containing potassium, or by eating foods rich in potassium (fruits, vegetables).

    Spironolactone (veroshpiron *, aldactone *, veropilactone *) in tablets, capsules, initial daily dose - 1.33 mg / kg, maximum - 3 mg / kg in 2 doses, or 30-90 mg / m 2, course - 2 weeks . Contraindicated in infancy.

    Furosemide (lasix *) in tablets of 40 mg and granules for suspension, ampoules 1% - 2 ml. Newborns are prescribed 1-4 mg/kg per day 1-2 times, 1-2 mg/kg IV or IM 1-2 times a day, children - 1-3 mg/kg per day, adolescents - 20 -40 mg / day.

    Diuretic drugs are prescribed in the morning. It is necessary to control the level of potassium in the blood serum, ECG.

    The criterion for the effectiveness of the therapy is a positive water balance, which is 200-400 ml/day with a small amount of ascites and 500-800 ml/day with edematous ascitic syndrome in older children. Paracentesis perform according to strict indications (with a large amount of liquid) with the simultaneous administration of albumin in the amount of 4-5 g / in. With the ineffectiveness of drug therapy, surgical treatment (bypass surgery) is possible.

    Hemostatic therapy (ε-aminocaproic acid, vikasol*, calcium gluconate, dicynone*, erythrocyte mass).

    Restoration of the volume of circulating blood (albumin solution, plasma).

    Pharmacological reduction of portal pressure (vasopressin, somatostatin, octreotide).

    Mechanical tamponade of the esophagus (Sengstaken-Blackmore probe).

    Endoscopic methods of stopping bleeding (sclerotherapy with ethanolamine, polidocanol, ligation of vein trunks).

    Transjugular intrahepatic portosystemic shunt.

    Prevention of stress ulcers of the gastrointestinal tract (blockers of H2-histamine receptors, PPIs).

    Prevention of hepatic encephalopathy (lactulose, siphon enemas).

    Prevention of spontaneous bacterial peritonitis (antibiotics).

    Main pharmacological agents with hemorrhagic syndrome

    ε-Aminocaproic acid for intravenous administration and in granules for the preparation of a suspension for oral administration, the daily dose for children under 1 year is 3 g; 2-6 years - 3-6 g, 7-10 years - 6-9 g.

    Menadione sodium bisulfate (Vikasol *) 1% solution is prescribed for children under 1 year - 2-5 mg / day, 1-2 years - 6 mg / day, 3-4 years - 8 mg / day, 5-9 years - 10 mg / day, 10-14 years - 15 mg / day. The duration of treatment is 3-4 days, after a 4-day break, the course is repeated.

    Etamsylate (dicynone *) is produced in tablets of 250 mg and as a 12.5% ​​solution in ampoules of 2 mg (250 mg per ampoule) for intramuscular and intravenous administration. When bleeding, children under 3 years of age are administered 0.5 ml, 4-7 years - 0.75 ml, 8-12 years - 1-1.5 ml and 13-15 years - 2 ml. The indicated dose is repeated every 4-6 hours for 3-5 days. In the future, treatment with dicynone * can be continued in tablets (daily dose - 10-15 mg / kg): children under 3 years old - 1/4 tablet, 4-7 years old - 1/2 tablet, 8-12 years old - 1 tablet each and 13-15 years - 1.5-2 tablets 3-4 times a day.

    Means for strengthening the vascular wall - flavonoid troxerutin, ascorbic acid + rutoside (ascorutin *).

    To reduce portal pressure, desmopressin (minirin *) is used - an analogue of the natural hormone arginine-vasopressin, 100-200 mg at night.

    Treatment malignant neoplasm liver carried out by specialists of the oncology center. Indications for splenectomy

    Segmental extrahepatic portal hypertension.

    Severe hypersplenism with hemorrhagic syndrome.

    Lag in the physical and sexual development of children with cirrhosis of the liver.

    Giant splenomegaly with severe pain syndrome (heart attacks, perisplenitis).

    Treatment spontaneous bacterial peritonitis carry out cephalosporins III-IV generation.

    A radical treatment for cirrhosis of the liver is liver transplantation.

    Prevention

    basis secondary prevention is a timely etiotropic and pathogenetic treatment of acute and chronic hepatitis.

    Prevention of cirrhosis in essence tertiary and quaternary, since they carry out treatment aimed at stabilizing the pathological process in the liver, preventing exacerbations, reducing the risk of development and progression of complications. Children should be under dynamic supervision in specialized clinics and centers, and on an outpatient basis - under the supervision of a pediatrician and a gastroenterologist. Immunoprophylaxis is carried out strictly individually.

    Prevention of complications, for example, the first bleeding from varicose veins of the esophagus, is possible due to endoscopic examination at least 1 time in 2-3 years in order to dynamically monitor their likely development. The condition of patients with the initial stage of varicose veins of the esophagus is monitored endoscopically once every 1-2 years. Preventive treatment is carried out with moderate and severe.

    Forecast

    The prognosis of liver cirrhosis is unfavorable and, as a rule, uncertain and unpredictable, as it depends on the cause of cirrhosis, the age of the patient, the stage of the disease, and the possibility of unforeseen fatal complications. By itself, cirrhosis of the liver is incurable (except in cases where a liver transplant has been done), but the correct treatment of cirrhosis allows for a long time (20 years or more) to compensate for the disease. Compliance with the diet, traditional and alternative methods of treatment (Fig. 6-16), the rejection of bad habits significantly increase the patient's chances of compensating for the disease.

    Rice. 6-16. Treatment options for patients with cirrhosis

    Without surgical treatment, children with biliary atresia die at the 2-3rd year of life. The earlier the operation is performed, the better the prognosis. About 25-50% of early operated children survive 5 years or more when they receive a liver transplant. The outcome depends on the presence or absence of an inflammatory and sclerotic process in the liver.

    LIVER FAILURE

    ICD-10 codes

    K72. Liver failure. K72.0. Acute and subacute liver failure. K72.1. Chronic liver failure. K72.9. Liver failure, unspecified.

    Liver failure is a complex of symptoms characterized by a violation of one or more functions of the liver, resulting from damage to its parenchyma (hepatocellular or hepatocellular insufficiency syndrome). Portosystemic or hepatic encephalopathy is a symptom complex of CNS disorders that occurs with liver failure with a profound impairment of numerous vital liver functions.

    Mortality from liver failure is 50-80%. In acute liver failure, hepatic encephalopathy may develop, which is rare in acute liver diseases, but mortality can reach 80-90%.

    Etiology and pathogenesis

    Acute liver failure occurs in severe forms of viral hepatitis A, B, C, D, E, G, poisoning with hepatotropic poisons (alcohol, some drugs, industrial toxins, mycotoxins and aflatoxins, carbon dioxide, etc.). Its causes may be herpes viruses, cytomegalovirus, infectious mononucleosis virus, simple and herpes zoster, Coxsackie virus, the causative agent of measles; septicemia in liver abscesses. Acute liver failure is described in toxic hepatoses (Reye's syndrome, a condition after the small intestine is turned off), Wilson-Konovalov's disease, Budd-Chiari syndrome.

    Budd-Chiari Syndrome(ICD-10 code - I82.0) develops due to progressive narrowing or closure of the hepatic veins. On the basis of thrombophlebitis of the umbilical vein and the Arantzian duct, which flows into the mouth of the left hepatic vein, Budd-Chiari syndrome can begin in early childhood. As a result, stagnation develops in the liver with compression of the liver cells.

    Reye's syndrome(ICD-10 code - G93.7) - acute encephalopathy with cerebral edema and fatty liver that occurs in previously healthy newborns, children and adolescents (usually at the age of 4-12 years), associated with a previous viral infection (for example, chickenpox smallpox or influenza type A) and taking drugs containing acetylsalicylic acid.

    Chronic liver failure is a consequence of the progression of chronic liver diseases (hepatitis, liver cirrhosis, malignant liver tumors, etc.). The main etiological factors are shown in fig. 6-17, a.

    At the basis of pathogenesis liver failure there are two processes. Firstly, severe dystrophy and widespread necrobiosis of hepatocytes lead to a significant decrease in liver function. Secondly, due to the numerous collaterals between the portal and vena cava, a significant part of the absorbed toxic products enters the systemic circulation bypassing the liver. Poisoning is caused by non-neutralized protein breakdown products, end products of metabolism (ammonia, phenols).

    emergence hepatic encephalopathy in liver failure, it is associated with disturbances in homeostasis, acid-base state and electrolyte composition of the blood (respiratory and metabolic alkalosis, hypokalemia, metabolic acidosis, hyponatremia, hypochloremia, azotemia). Cerebrotoxic substances enter the systemic circulation from the gastrointestinal tract and liver: amino acids and their decay products (ammonia, phenols, mercaptans); products of hydrolysis and oxidation of carbohydrates (lactic, pyruvic acid, acetone); products of impaired fat metabolism; false neurotransmitters (asparagine, glutamine), which have toxic effects on the central nervous system. The mechanism of damage to brain tissue is associated with impaired function of astrocytes, which make up approximately 30% of brain cells. Astrocytes play a key role in regulating the permeability of the blood-brain barrier, in ensuring the transport of neurotransmitters to brain neurons, and in the destruction of toxic substances (in particular, ammonia) (Fig. 6-17, b).

    Rice. 6-17. Chronic liver failure and hepatic encephalopathy: a - etiology of liver failure; b - the mechanism of formation of hepatic encephalopathy

    ammonia exchange. At healthy people In the liver, ammonia is converted to uric acid in the Krebs cycle. It is required in the conversion of glutamate to glutamine, which is mediated by the enzyme glutamate synthetase. In chronic liver damage, the number of functioning hepatocytes decreases, creating prerequisites for hyperammonemia. When portosystemic shunting occurs, ammonia, bypassing the liver, enters the systemic circulation - hyperammonemia occurs. Ammonia, acting

    in the brain, leads to disruption of the functioning of astrocytes, causing morphological changes in them. As a result, with liver failure, cerebral edema occurs, and intracranial pressure increases.

    Under conditions of liver cirrhosis and portosystemic shunting, the activity of skeletal muscle glutamate synthetase increases, where the process of ammonia destruction begins to occur. This explains the decrease in muscle mass in patients with cirrhosis of the liver, which, in turn, also contributes to hyperammonemia. The processes of metabolism and excretion of ammonia also occur in the kidneys.

    Clinical picture

    The clinical picture is manifested by disorders of consciousness and cognitive functions, drowsiness, monotonous speech, tremor, and discoordination of movements. Especially important signs are a rapid decrease in the size of the liver, its softening and pain on palpation. In table. 6-14 briefly summarizes the clinical manifestations by stages of liver failure and encephalopathy, the differences between acute and chronic liver failure - in table. 6-15.

    Table 6-14. Classification of stages of liver failure and encephalopathy

    Table 6-15. Differential diagnosis of acute and chronic liver failure

    Hepatic coma is preceded by general excitation, which turns into oppression of consciousness: stupor and stupor, then its complete loss occurs. Appear meningeal phenomena, pathological reflexes (grasping, sucking), restlessness, convulsions. Breathing becomes arrhythmic, like Kussmaul or Cheyne-Stokes. Pulse small, irregular. From the mouth and from

    the skin emits a liver smell (feetor hepatica), due to the release of methyl mercaptan; jaundice and hemorrhagic syndrome increase, ascites, hypoproteinemic edema increase (Fig. 6-18, a). Clinical manifestations of the decompensated and terminal stages are clearly shown in Fig. 6-18, Gd. The term "malignant form" (the most severe form) refers to a qualitatively new clinical condition that occurs in patients with viral hepatitis B if they develop massive or submassive liver necrosis.

    Rice. 6-18. Liver failure: a - clinical manifestations; a and b - decompensated stage; c - terminal stage ("floating eyeball"); d - hepatic coma

    Over the next 2-3 days, a deep hepatic coma develops. Sometimes a coma occurs, bypassing the stage of excitement.

    Diagnostics

    Conduct laboratory and instrumental studies.

    In the general blood test, anemia, leukocytosis, thrombocytopenia, and an increase in ESR are detected.

    In a biochemical study, bilirubinemia, azotemia, hypoalbuminemia, hypocholesterolemia are diagnosed, the levels of ALT, AST, alkaline phosphatase increase, the levels of fibrinogen, potassium, sodium, prothrombin index decrease, metabolic acidosis is noted.

    Ultrasound, CT scan of the liver reveals a change in the size and structure of the liver parenchyma.

    Pathomorphology

    Morphological changes in the liver relate to all its tissue components: parenchyma, reticuloendothelium, connective tissue stroma, and to a lesser extent - biliary tract.

    Distinguish three variants of the acute form of the disease:

    Acute cyclic form;

    Cholestatic (pericholangiolytic) hepatitis;

    Massive necrosis of the liver.

    The severity of morphological changes depends on the severity and etiology of the disease (Fig. 6-19, a, b). At the height of the disease, alternative, exudative processes predominate; during the recovery period, the processes of proliferation and regeneration prevail.

    Rice. 6-19. Liver necrosis, macro- and micropreparations: a - etiology is unknown; b - adenovirus etiology; c - χ 250; d - χ 400 (hematoxylin-eosin staining)

    In cholestatic (pericholangiolytic) hepatitis, morphological changes mainly concern the intrahepatic bile ducts (cholangiolitis and pericholangiolitis).

    Liver necrosis is an extreme degree of changes in the liver, which can be massive, when almost the entire hepatic epithelium dies or a small border of cells remains along the periphery of the lobules, or submassive, in which most hepatocytes undergo necrobiosis, mainly in the center of the lobules (Fig. 6-19 , c, d).

    Differential Diagnosis

    For the purposes of differential diagnosis, it is necessary to exclude extrahepatic causes of symptoms from the CNS. The level of ammonia in the blood is determined upon admission to the hospital of a patient with cirrhosis of the liver and signs of CNS damage. It is necessary to establish the presence in the patient's history of such pathological conditions as metabolic disorders, gastrointestinal bleeding, infections, constipation.

    If symptoms of hepatic encephalopathy occur, a differential diagnosis is made with diseases that include the following.

    intracranial pathological conditions: subdural hematoma, intracranial bleeding,

    stroke, brain tumor, brain abscess.

    Infections: meningitis, encephalitis.

    Metabolic encephalopathy, which developed against the background of hypoglycemia, electrolyte disturbances, uremia.

    Hyperammonemia caused by congenital anomalies of the urinary tract.

    Toxic encephalopathy caused by alcohol intake, acute intoxication, Wernicke's encephalopathy.

    Toxic encephalopathy that arose while taking medications: sedatives and antipsychotics, antidepressants, salicylates.

    Postconvulsive encephalopathy.

    Treatment

    Treatment consists in limiting the amount of protein in the diet, the appointment of lactulose. Patients with hepatic encephalopathy are candidates for liver transplantation.

    In the complex of therapeutic measures for liver failure, there are stages (Fig. 6-20), as well as basic (standard) therapy and a number of more radical means aimed at cleansing the body of toxic products of metabolic disorders, as well as replacing (temporary or permanent) functions the affected liver.

    Basic therapy acute liver failure is aimed at correcting the electrolyte, energy balance, acid-base state, vitamins and cofactors, disorders of the blood coagulation system, hemocirculation, elimination of hypoxia, prevention of complications, prevention of absorption of putrefactive decay products from the intestine. Basic therapy also includes the use of glucocorticoids.

    General principles of managing a patient with acute liver failure

    Individual post of a nurse.

    Monitor urinary output, blood glucose and vital signs every hour.

    Rice. 6-20. Stages of treatment of hepatic encephalopathy

    Control of potassium in the blood serum 2 times a day.

    Blood test, determination of the content of creatinine, albumin, assessment of the coagulogram daily.

    Prevention of bedsores.

    General principles of managing a patient with chronic liver failure

    Active monitoring of the patient's condition, taking into account the severity of symptoms of encephalopathy.

    Daily weighing of the patient.

    Daily assessment of the balance of fluids drunk and excreted per day.

    Daily determination of blood tests, electrolytes, creatinine.

    Determination 2 times a week of the content of bilirubin, albumin, activity of AST, ALT, alkaline phosphatase.

    Coagulogram, prothrombin content.

    Evaluation of the need and possibility of liver transplantation in the final stage of liver cirrhosis.

    Treatment of hepatic encephalopathy

    Elimination of provoking factors.

    Stop gastrointestinal bleeding.

    Suppression of the growth of proteolytic microflora in the colon and treatment of infectious diseases.

    Normalization of electrolyte disorders.

    Reducing the degree of hyperammonemia:

    a) reduction of ammoniacogenic substrate:

    Cleansing the gastrointestinal tract (siphon enemas, laxatives);

    Decreased protein intake;

    b) the binding of ammonia in the blood:

    Ornithine (hepa-merz*);

    c) suppression of ammonia formation:

    Broad spectrum antibiotics;

    Acidification of intestinal contents with lactulose. Enemas are recommended to reduce ammonia levels.

    or the use of laxatives for bowel movements at least 2 times a day. For this purpose, lactulose (Normaze *, dufalac *) is prescribed in syrup, 20-50 ml orally every hour until diarrhea appears, then 15-30 ml 3-4 times a day. For use in an enema, up to 300 ml of the drug is diluted in 500-700 ml of water.

    Before the patient is discharged from the hospital, the dose of lactulose should be reduced to 20-30 ml at night, with a possible subsequent cancellation at the outpatient stage.

    To radical methods treatment include the following measures to massively remove toxic products from the patient's blood.

    controlled hemodilution.

    Plasmapheresis.

    Exchange transfusion.

    Temporary (or permanent) replacement of the patient's liver by extracorporeal connection of xeno-liver (pork), cross-circulation.

    Hetero- and orthotopic liver transplantation.

    Prevention

    The best way to prevent liver failure is to prevent the risk of developing cirrhosis or hepatitis. This requires specific immunization, compliance is important healthy lifestyle life, rules of personal hygiene, diet therapy.

    The introduction of a specific immunoglobulin in case of an accidental transfusion of infected blood and at the birth of a child in a mother - a carrier of HBsAg or a patient with hepatitis B will allow passive immunization. Active immunization - vaccination of a child on the first day after birth, unvaccinated children of any age, as well as persons from risk groups: professional (doctors, emergency workers, military, etc.), persons on program hemodialysis, etc. (revaccination every 7 years). Vaccination against viral hepatitis B protects against infection with hepatitis D.

    Forecast

    When the cause of liver failure is eliminated, the manifestations of hepatic encephalopathy can be reduced. Chronic hepatic coma is fatal, however, with acute hepatocellular insufficiency, recovery is sometimes possible. With the development of hepatic encephalopathy, mortality can reach 80-90%.

    The development of fatty hepatosis is based on the violation of metabolic processes in the human body. As a result of this liver disease, healthy tissue of the organ is replaced by fatty tissue. At the initial stage of development, fat accumulates in hepatocytes, which over time simply leads to dystrophy of the liver cells.

    If the disease is not diagnosed at an early stage and appropriate therapy is not carried out, then irreversible inflammatory changes occur in the parenchyma, which lead to the development of tissue necrosis. If fatty liver is not treated, it can develop into cirrhosis, which is no longer treatable. In the article, we will consider the reason for the development of the disease, methods of its treatment and classification according to ICD-10.

    Causes of fatty liver and its prevalence

    The causes of the development of the disease have not yet been exactly proven, but factors are known that can surely provoke the onset of this disease. These include:

    • completeness;
    • diabetes;
    • violation of metabolic processes (lipid);
    • minimal physical activity with a nutritious daily diet high in fat.

    Most cases of development of fatty hepatosis are recorded by physicians in developed countries with above-average living standards.

    Important! The disease affects all age groups, from overweight children to the elderly with diabetes.

    There are a number of other factors associated with hormonal disruptions, such as insulin resistance and the presence of sugar in the blood. You can not omit the hereditary factor, it also plays a big role. But still the main reason is malnutrition, sedentary lifestyle and excess weight. All causes are in no way related to the intake of alcoholic beverages, so fatty hepatosis is often called non-alcoholic. But if alcohol addiction is added to the above reasons, then fatty hepatosis will develop many times faster.

    In medicine, it is very convenient to use the coding of diseases to systematize them. It is even easier to indicate a diagnosis on a sick leave using a code. Codes for all diseases are presented in the International Classification of Diseases, Injuries and Various Health Problems. The tenth revision is currently in effect.

    All liver diseases according to the International Classification of the Tenth Revision are encrypted under the codes K70-K77. And if we talk about fatty hepatosis, then according to ICD 10, it falls under the code K76.0(fatty degeneration of the liver).

    Treatment of fatty liver

    The treatment regimen for non-alcoholic hepatosis is to eliminate possible risk factors. If the patient is obese, then you need to try to optimize it. And start by reducing the total mass by at least 10%. Doctors recommend using minimal physical activity in parallel with dietary nutrition to achieve the goal. Limit the use of fats in the diet as much as possible. At the same time, it is worth remembering that a sharp weight loss will not only not be beneficial, it can, on the contrary, damage, aggravating the course of the disease.

    Important! Drug therapy consists only in correcting the disturbed carbohydrate metabolism.

    For this purpose, the attending physician may prescribe thiazolidinoids in combination with biguanides, but this line of drugs has not yet been fully studied, for example, for hepatotoxicity. Metformin can help correct the process of metabolic disorders in carbohydrate metabolism.

    As a result, we can confidently say that with the normalization of the daily diet, a decrease in body fat and giving up bad habits, the patient will feel better. And only in this way it is possible to fight such a disease as non-alcoholic hepatosis.

    You may find this useful: